



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number:

0 214 826 B1

⑫

EUROPEAN PATENT SPECIFICATION

⑯ Date of publication of patent specification: 19.10.94 ⑮ Int. Cl. 5: C07K 7/10, C07K 7/40, C12P 21/02, C12N 15/00, A61K 37/26
⑯ Application number: 86306721.1
⑯ Date of filing: 29.08.86

The file contains technical information submitted after the application was filed and not included in this specification

⑯ Insulin analogues and method of preparing the same.

⑯ Priority: 30.08.85 DK 3956/85
14.10.85 DK 4677/85

⑯ Date of publication of application:
18.03.87 Bulletin 87/12

⑯ Publication of the grant of the patent:
19.10.94 Bulletin 94/42

⑯ Designated Contracting States:
AT BE CH DE FR GB IT LI LU NL SE

⑯ References cited:
EP-A- 0 163 529
EP-A- 0 195 691
US-A- 4 343 898

Nature, vol. 284, March 6, 1980, pp. 26-32; G.I. Bell et al.

Hoppe-Seyler's Z. Physiol. Chem., vol. 360, Nov. 1979, pp. 1619-1632; F. Marki et al.

Nature, vol. 284, March 6, 1980, pp. 26-32; G.I. Bell et al.

Chemical Abstracts, vol. 98, no. 7, Febr. 14,

1983, p. 727, ref. no. 54445r, Columbus, Ohio, US; S. Chu et al.

⑯ Proprietor: NOVO NORDISK A/S
Novo Allé
DK-2880 Bagsvaerd (DK)

⑯ Inventor: Brange, Jens Jorgen Vejlgaard
Kroyersvej 22C
DK-2930 Klampenborg (DK)
Inventor: Norris, Kjeld
Ahlmanns Alle 34
DK-2900 Hellerup (DK)
Inventor: Hansen, Mogens Trier
Mosevang 9
DK-3540 Lyng (DK)

⑯ Representative: Brown, John David et al
FORRESTER & BOEHMERT
Franz-Joseph-Strasse 38
D-80801 München (DE)

EP 0 214 826 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

The present invention relates to novel human insulin analogues characterized by a rapid onset of effect on subcutaneous injection and to injectable insulin solutions containing such insulin analogues and to methods for the preparation of the novel insulin analogues.

BACKGROUND OF THE INVENTION

In the treatment of Diabetes mellitus many varieties of insulin preparations have been suggested to the art. Some of these preparations are rapid-acting and others have a more or less prolonged action.

Rapid acting insulin preparations may be used in acute situations, such as hyperglycemic coma, during surgery, during pregnancy, and in severe infections. Furthermore, multiple, daily injections of rapid-acting insulin preparations may improve control in diabetics who have proved difficult to control with longer-acting insulin.

In the recent years there has been an increasing interest in an insulin treatment which approaches the insulin secretion from the beta cells of the healthy organism, i.e. supply of insulin in connection with meals and maintenance of a basal insulin level. Clinical investigations have shown that diabetics can obtain normal insulin and glucose concentrations by means of one daily injection of insulin with prolonged action to cover the basal need, supplemented with injections of smaller amounts (bolus) of rapid-acting insulin before the main meals.

Rapid-acting insulins are also used in mixtures with intermediate and long-acting insulins for treatment of diabetics requiring a stronger initial effect in addition to the delayed action of intermediate and long-acting insulins.

Finally, rapid-acting insulin is used in continuous insulin delivery systems.

By subcutaneous injection of rapid-acting insulin solutions an initial delay in absorption has been observed (Binder, *Diabetes Care* 7, No. 2 (1984), 188-199). A delay in absorption resulting in a slower onset of action is however undesirable when a strict metabolic control is aimed at. Mixing of rapid-acting insulin solutions with longer-acting insulin preparations may furthermore result in reduced rate of absorption of the rapid-acting insulin.

Accordingly, there is a need for rapid-acting insulin solutions with a faster onset of action upon subcutaneous injection and an improved miscibility with protracted insulin preparations.

A further drawback of known rapid-acting insulin solution is the tendency of insulin to fibrillate and precipitate out in the insulin solutions used for continuous insulin delivery thereby obstructing mechanical parts and delivery catheters.

Finally there is a need for alternative insulin preparations for the treatment of patients resistant to normal insulin.

It is the object of the present invention to provide novel rapid-acting insulin solutions with one or more of the following improved properties:

- 1) faster onset of action by subcutaneous injection or other routes of administration
- 2) improved miscibility with protracted insulin preparations
- 3) reduced tendency to fibrillation when used in implantable delivery systems, and
- 4) usable for the treatment of resistant patients (low affinity for preexisting antibodies).

The objectives of this invention are achieved with injectable aqueous solutions of the novel human insulin analogues hereinafter described.

A large number of insulin analogues have been described in the past. Märki et al. (*Hoppe-Seyler's Z. Physiol. Chem.*, 360 (1979), 1619-1632) describe synthesis of analogues of human insulin that differ from human insulin in the replacement of a single amino acid in positions 2, 5, 6, 7, 8, and 11 of the A-chain and 5, 7, 13, and 16 of the B-chain affording new insights into the intriguing structure-activity relationship of insulin. Further studies modified the major receptor binding area in insulin (B(22)-B(26)) to investigate the impact of such mutation on the receptor binding activity. The known human insulin analogues will, however, not exhibit the properties desired by the inventors hereof.

US Patent No 3 883 496 refers to various substitutions in the insulin molecule, whilst *Chemiker Zeitung*, 100 Jahrgang (1976), No 3, page 20 discloses B(9) → Ala and B(10) → Ala, as well as Ala substitutions at B(9) and B(27); B(9), B(27) and B(28); B(10) and B(28); B(5) and B(28); B(5), B(10), B(27) and B(28); B(5), B(9), B(27) and B(28); B(5), B(9), B(10), B(27) and B(28); etc, etc. However neither of these documents discloses rapid acting analogues of insulin.

It is known that sulphated insulins have a substantially lower tendency to fibrillation (Albisser et al., *Desired Characteristics of insulin to be used in infusion pumps*. In: Guerigian J.L. et al., eds. US

Pharmacopeial Convention, Rockville, Maryland, pp. 84-95) and exhibit a low antigenicity. Sulphated insulins are, however, a heterogeneous mixture of at least nine different insulin derivatives containing on average 4.5 sulphate ester groups per molecule. Sulphated insulins have furthermore a reduced insulin activity, being about 20% of the activity of native insulin. A further drawback of sulphated insulins as compared to native insulin is that they needlessly contain amino acid residues which are chemically modified, i.e. amino acids which do not occur naturally.

It is therefore a further object of the present invention to provide insulin analogues which are homogeneous, have a higher biological activity than sulphated insulins and which furthermore preferably only contain naturally occurring amino acids.

By "insulin analogues" as used herein is meant a compound having a molecular structure similar to that of human insulin including the disulphide bridges between A(7)Cys and B(7)Cys and between A(20)Cys and B(19)Cys and an internal disulphide bridge between A(6)Cys and A(11)Cys and with insulin activity.

SUMMARY OF THE INVENTION

The present invention is based on the surprising fact that certain insulin analogues, in which at least one of the amino acid residues of human insulin has been substituted with naturally occurring amino acid residues, exhibit the desired rapid acting activity.


In its broadest aspect the present invention provides novel, rapid-acting human insulin analogues formed by substituting one or more of the amino acid residues of human insulin with naturally occurring amino acid residues giving rise to less self-association into dimers, tetramers, hexamers, or polymers, and having the same charge or a greater negative charge at neutral pH than that of human insulin.

To provide a reduced tendency to self-association into dimers, tetramers, hexamers, or polymers certain residues of human insulin are preferably substituted with other amino acid residues being more hydrophilic than the natural amino acid residue at the respective position in the molecule. Also, at certain positions in the insulin molecule substitution with a more bulky amino acid residue will give rise to a reduced tendency of the insulin molecules to associate into dimers, tetramers, hexamers, or polymers.

More specifically the present invention provides novel insulin derivatives with the following general formula (I):

30

A - chain



B - chain

50

wherein at least one but not more than seven of the X's are the same or different amino acid residue substitutions, the net function of which are to impart to the molecule the same charge or a greater negative charge at neutral pH than that of human insulin, the remaining X's being the natural amino acid residues of human insulin at the respective position in the insulin molecule with the proviso that there is at least one substitution in the B-chain and that when X in position B(5) is Ala, X in position B(9) is Leu, X in position B(10) is Asn or Leu, X in position B(12) is Asn or X in position B(26) is Ala, then at least one of the remaining X's are different from the amino acid residues of human insulin at the respective position in the insulin molecule, and with the further proviso that X in position B(5) can not be Asp and X in position B(12) can not

be Glu, and wherein one or more amino acid residues may have been removed from the N- and/or C-terminal ends of the A- and/or B-chain, with the additional proviso that, when X is Ala in one or more of positions B(1), B(2), B(5), B(9), B(10), B(27) or B(28), then at least one of any of the X's, except any X which is Ala in position B(1), B(2), B(5), B(9), B(10), B(27) and/or B(28), is different from the amino acid residues of human insulin at the respective position in the insulin molecule and methods for preparing such insulin analogues

Preferably at least a majority of the amino acid residue substitutions are more hydrophilic than the amino acid residue at the corresponding site in the human insulin molecule and more preferably all amino acid residue substitutions are more hydrophilic than the corresponding human insulin amino acid residues.

With respect to hydrophilicity reference is made to C. Frömmel, J. Theor. Biol. 111 (1984), 247-260 (table 1).

With reference to the above formula I, most preferred are 2 to 4 substitutions.

PREFERRED EMBODIMENTS OF THE INVENTION

The amino acid residues substitutions are preferably chosen among the group consisting of Asp, Glu, Ser, Thr, His, and Ile and are more preferably negatively charged amino acid residues, i.e. Asp and/or Glu.

The novel human insulin analogue may preferably contain Asp and/or Glu instead of one or more of the hydroxy amino acids of human insulin, or instead of one or more Gln and Asn of human insulin.

The novel human insulin analogues may furthermore preferably contain Ser and/or Thr or Asp and/or Glu instead of one or more of the amino acid residues of human insulin with an aliphatic and/or aromatic side chain.

The novel human insulin analogues may also preferably contain His instead of one or more of the amino acid residues of human insulin with an aliphatic and/or aromatic side chain or instead of one or more of the hydroxy amino acids of human insulin.

Preferred sites of substitutions are at the sites B9, B10, B12, B26, B27, and B28, preferably B9, B12, B27, and B28, in which positions one substitution can be sufficient for obtaining a reduced tendency to self-association and a more rapid-action by administration.

The amino acid residue substitution in position B9 may be chosen from the group consisting of Asp, Pro, Glu, Ile, Leu, Val, His, Thr, Gln, Asn, Met, Tyr, Trp and Phe and more preferably from the group consisting of Asp, Glu, Gln, Asn, and His.

The amino acid residue substitution in position B12 may be chosen from the group consisting of Ile and Tyr, but cannot be Glu. The amino acid residue substitution in position B10 may be chosen from the group consisting of Asp, Arg, Glu, Asn, and Gln and in positions B26, B27, and B28 the amino acid residue substitutions are preferably Asp or Glu.

In the remaining positions of the insulin molecule at least two substitutions (preferably in combination with the above mentioned positions) seem to be necessary to obtain the improved properties. In these positions substitutions may be made as follows:

40

45

50

55

Position	Preferred amino acid residue substitutions
A8	His, Gly, Gln, Glu, Ser, Asn, Asp, Pro
5 A9	Gly, Asp, Glu, Thr, His, Gln, Asn, Ala, Pro
A10	Leu, Pro, Val, His, Ala, Glu, Asp, Thr, Gln, Asn
A13	Pro, Val, Arg, His, Ala, Glu, Asp, Thr, Gly, Gln, Asn, Asp
10 A21	Asp, Glu
B1	Glu, Asp, Thr, Ser
B2	Arg, His, Ala, Glu, Asp, Thr, Pro, Gly, Gln, Ser, Asn
15 B5	Glu, Thr, Ser, Gln, Asn
B14	Glu, Asp, Asn, Gln, Ser, Thr, Gly
B16	Asp, Glu, Gln, Asn, Ser, Thr, His, Arg
20 B17	Ser, Thr, Asn, Gln, Glu, Asp, His
B18	Ser, Thr, Asn, Gln, His
B20	Gln, Ser, Asn, Asp, Glu, Arg

25 Further preferred compounds of the present invention are insulin analogues in which substitutions are at the following sites: B27, B12, B9, (B27+B9), (B27+A21), (B27+B12), (B12+A21), (B27+B17), (B27+A13), (B27+B16), (B27+A10), (B27+B28), (B27+B26), (B27+B10), (B27+B1), (B27+B2), (B27+B5), (B27+B14), (B27+B18), (B27+B20), (B12+B17), (B12+A10), (B12+A13), (B12+B16), (B12+B1), (B12+B2), (B12+B5), (B12+B10), (B12+B26), (B12+B28), (B9+B17), (B9+A13), (B9+B16), (B9+A8), (B9+A9), (B9+A10), (B9+B1), (B9+B2), (B9+B5), (B9+B10), (B9+B12), (B9+B14), (B9+B28), (B9+B18), (B9+B20), (B9+B26), (B27+B9+A21), (B9+B27+A8), (B27+B12+A21), (B27+B12+B9), (B9+B12+B27+B17), (B9+B12+B27+A13), (B9+B12+B27+B16) and (B12+B16+B17+B27+A10+A13).

35


40

45


50

55


Preferred embodiments of the above formula I are as follows:



15



35



in which the X's are defined as above.

Referring to formula I other preferred insulin analogues according to the present invention are such in which X in position B27 is Glu, X in position B12 is Ile or Tyr, X in position A21 is Asp and in position B27 is Glu, X in position B9 is Asp, X in position A21 and in position B9 is Asp and in position B27 is Glu, X in position A8 in His, in position B9 is Asp and in position B27 is Glu, X in position B10 is Asp, X in position B28 is Asp, or X in position B9 is Asp and in position B27 is Glu.

According to a second aspect of the present invention there are provided injectable solutions with insulin activity. The injectable insulin solutions of this invention contain the human insulin analogues

described above or a pharmaceutically acceptable salt thereof in aqueous solution preferably at neutral pH. The aqueous medium may be made isotonic by addition of for example sodium chloride and glycerol. Also buffers, such as an acetate or citrate and preservatives, such as m-cresol, phenol or methyl 4-hydroxy benzoate may be added. The insulin solutions may furthermore contain zinc ions.

5 The human insulin analogues of this invention may be substituted for human or porcine insulin in the rapid acting insulin solutions heretofore known to the art.

PREPARATION OF THE INSULIN ANALOGUES


10 After the advent of the recombinant DNA-technology the possibilities for the protein engineering has become to be enormous. By the socalled site specific mutagenesis technique it is possible to alter a gene coding for a naturally occurring protein by substituting any one or more of the codons in the native gene with codon(s) for other naturally occurring amino acid(s). Alternatively the modified gene may be made by chemical synthesis of the total DNA-sequence by well known technique. The purpose of such manipulation 15 of a gene for a natural protein will typically be to alter the properties of the natural protein in one or another aimed direction.

20 The novel insulin analogues may be prepared by altering the proinsulin gene through replacement of codon(s) at the appropriate site in the native human proinsulin gene by codon(s) encoding the desired amino acid residue substitute(s) or by synthesizing the whole DNA-sequence encoding the desired human 25 insulin analogue. The novel modified or synthetic gene encoding the desired insulin analogue is then inserted into a suitable expression vector which when transferred to a suitable host organism, e.g. E. coli, Bacillus or a yeast, generates the desired product. The expressed product is then isolated from the cells or the culture broth depending on whether the expressed product is secreted from the cells or not.

25 The novel insulin analogues may also be prepared by chemical synthesis by methods analogue to the method described by Märki et al. (Hoppe-Seyler's Z. Physiol. Chem., 360 (1979), 1619-1632). They may also be formed from separately in vitro prepared A- and B-chains containing the appropriate amino acid residue substitutions, whereupon the modified A- and B-chains are linked together by establishing disulphide bridges according to known methods (e.g. Chance et al., In: Rick DH, Gross E (eds) Peptides: 30 Synthesis - Structure - Function. Proceedings of the seventh American peptid symposium, Illinois, pp 721-728).

The novel insulin analogues are preferably prepared by reacting a biosynthetic precursor of the general formula II:

35 **A - chain:**



55 **B - chain:**

wherein Q_n is a peptide chain with n naturally occurring amino acid residues, R is Lys or Arg, n is an integer from 0 to 33, m is 0 or 1, and the X 's are defined as above with the proviso that the peptide chain $-Q_n-R$ does not contain two adjacent basic amino acid residues, with an L-threonine ester in the presence of trypsin or a trypsin derivative followed by conversion of the obtained threonine ester of the human insulin analogue into the human insulin analogue by known methods. This socalled "transpeptidation" reaction is


described in US patent specification No. 4,343,898 (the disclosures of which are incorporated by reference hereinto).

By the transpeptidation reaction the bridging $-(Q_n-R)_m-$ between amino acid 29 in the B chain and amino acid 1 in the A chain is excised and a threonine ester group is coupled to the C terminal end of B29Lys.

5 The precursors of the above formula II may be prepared by a method analogue to the method described in EP patent application No. 0163529A the disclosure of which is incorporated by reference hereinto. By this method a DNA-sequence encoding the precursor in question is inserted in a suitable expression vehicle which when transferred to yeast is capable of expressing and secreting the desired compound with correctly positioned disulphide bridges. The expressed product is then isolated from the culture broth.

10 The present insulin analogues may also be prepared by reacting a biosynthetic precursor of the general formula III:

A - chain



B - chain

wherein V and T are each Lys or Arg and the X's are defined as above, in aqueous solution with trypsin and carboxypeptidase B and recovering the human insulin analogue from the reaction solution.

35 The precursors of the above formula III may be prepared by a method analogue to the method described in EP patent application No. 86302133.3 the disclosure of which is incorporated by reference hereinto. By this method a DNA-sequence encoding the precursor is inserted into a suitable yeast expression vehicle which when transferred to yeast is capable of expression and secretion of the expressed product with correctly positioned disulphide bridges into the culture medium.

40 According to a third aspect of the present invention there is provided a method for producing of the novel insulin analogues by which method a yeast strain containing a replicable expression vehicle comprising a DNA-sequence encoding a precursor of the insulin analogue is cultured in a suitable nutrient medium, and the precursor is recovered from the culture medium and converted into the novel insulin analogue by enzymatic and chemical in vitro conversion.

45 The present invention is also directed to novel precursors of the novel insulin analogues, DNA sequences encoding such novel precursors, expression vehicles containing such DNA-sequences and yeast strains transformed with such expression vehicles.

MODIFIED INSULIN ANALOGUES

50 The present invention is contemplated to comprise certain derivations or further substitutions of the insulin analogues provided that such derivations or further substitutions have no substantial impact on the above-described goal of the invention. It is accordingly possible to derive one or more of the functional groups in the amino acid residues. Examples of such derivation is per se known conversion of acid groups in the insulin molecule into ester or amid groups, conversion of alcohol groups into alkoxy groups or vice versa, and selective deamidation. As an example A21Asn may be deamidated into A21Asp by hydrolysis in acid medium or B3Asn may be deamidated into B3Asp in neutral medium.

It is furthermore possible to modify the present insulin analogues by either adding or removing amino acid residues at the N- or C-terminal ends. The insulin analogues of the present invention may lack up to four amino acid residues at the N-terminal end of the B-chain and up to five amino acid residues at the C-terminal end of the B-chain without significant impact on the overall properties of the insulin analogue.

5 Examples of such modified insulin analogues are insulin analogue lacking the B1Phe or the B30Thr amino acid residue.

Also, naturally occurring amino acid residues may be added at one or more ends of the polypeptide chains provided that this has no significant influence on the above-described goal.

Such deletions or additions at the ends of the polypeptide chain of the present insulin analogues may 10 be exercised *in vitro* on the insulin analogues with amino acid substitutions according to the present invention. Alternatively the gene for the novel insulin analogues according to the present invention may be modified by either adding or removing codons corresponding to the extra amino acid residues or lacking amino acid residues at the ends of the polypeptide chain, respectively.

15 TERMINOLOGY

The abbreviations used for the amino acids are those stated in *J.Biol.Chem.* 243 (1968), 3558. The amino acids are in the L configuration.

As used in the following text B(1-29) means a shortened B chain of human insulin from B1Phe to 20 B29Lys and A(1-21) means the A chain of human insulin.

The substitution(s) made in the human insulin molecule according to the practice of the invention is(are) indicated with a prefix referenced to human insulin. As an example B27Glu human insulin means a human insulin analogue wherein Glu has been substituted for Thr in position 27 in the B chain. B27Glu,B9Asp human insulin means a human insulin analogue wherein Glu has been substituted for Thr in position 27 in 25 the B chain and Asp has been substituted for Ser in position 9 in the B chain. B27Glu,B(1-29)-Ala-Ala-Lys-A(1-21) human insulin means a precursor for the insulin analogue (see formula II) wherein Glu has been substituted for Thr in position 27 in the shortened B chain (see above) and wherein the B(1-29)-chain and the A-chain (A(1-21)) are connected by the peptide sequence Ala-Ala-Lys. Unless otherwise stated it is to be understood that the B(1-29) chain and A(1-21) chain are connected by disulphide bridges between A(7)-30 Cys and B(7)Cys and between A(20)Cys and B(19)Cys, respectively, as in human insulin and that the A chain contains the internal disulphide bridge between A(6)Cys and A(11)Cys.

EXPLANATION OF THE INVENTION

35 As has already been pointed out, the objective of this invention is to provide rapid acting injectable insulin solutions. In effort to meet this objective, the inventors hereof recognized first and foremost that considerable differences exist between insulin in a depot or bolus and insulin in the circulation, including notably a completely unavoidable difference in insulin concentration. Specifically, insulin in the bloodstream is highly dilute, being 10^{-11} to 10^{-8} M and is in monomer form, with possibly some insulin being in dimer form. The much more concentrated insulin stored in the B-cell granule of pancreas and in the usual 40 administerable solution is largely, if not principally, in the non-active hexamer form, for example, as the well-known 2 zinc hexamer.

Human insulin in solution is known to exist in many molecular forms, namely, the monomer, the dimer, the tetramer and the hexamer (Blundell et al. in *Advances in Protein Chemistry*, Academic Press, New York 45 and London, Vol. 26, pp. 279-330, 1972), with the oligomer forms being favored at high insulin concentrations and the monomer being the active form of insulin. The tetramer and hexamer are not active forms, and even the dimer may not be active. The concept underlying this invention is the inventor's belief that the art recognized delayed absorption phenomena (Binder, *Diabetes Care* 7, No. 2 (1984), 188-199) is in some large part attributable to the time required for the insulin to disassociate from hexamer, tetramer and dimer 50 form into the (active) monomer form.

The human insulin analogues of this invention achieve their rapid action through a molecular structure not readily susceptible of dimer, tetramer, hexamer, or polymer formation, i.e. with a reduced tendency to self-associate into dimers, tetramers, hexamers, or polymers with or without the presence of zinc ions.

It has long been recognized from the considerable species-to-species differences in amino acid 55 sequence which exist in insulin that not all of the amino acid residues present in the insulin molecule are crucial to insulin activity, and that some of the amino acids not essential to insulin activity are important to the physical properties of the insulin molecule. Indeed, guinea pig insulin is known to be incapable of dimerizing. Sulfated insulin and tetranitro tyrosine insulin do not dimerize. Thus many of the amino acid

residues in the human insulin molecule may be changed without substantial decrease in insulin activity. The amino acid substitutions in the human insulin molecule herein contemplated are directed to preventing formation of dimers, tetramers, hexamers, or polymers without destroying the insulin activity.

The amino acid residues in the positions in the A chain and the B chain of Formula I where substitutions may be made are not crucial to the insulin activity, but they are important to the capability of human insulin to aggregate into dimers, tetramers, hexamers, or polymers, or for the solubility of the human insulin. The present amino acid residue substitutions interfere with the atom-to-atom contacts between adjacent insulin molecules that facilitates aggregation into dimers, tetramers, hexamers or polymers.

As might be expected for substitution purposes, changes in certain positions in the human insulin molecule are more effective than others. By and large, a single substitution made in the B-chain may be sufficient to lessen the self-associating tendency, whereas at least two changes of other residues may be required. The substitutions in the A-chain mainly serve to improve the solubility of the dissociated molecule. Preferred positions for making amino acid residue substitutions are B9, B12, B10, B26, B27, and B28 alone, in combination with each other or together with substitutions elsewhere in the insulin molecule as indicated in formula I.

Manifestly, substitution of one or more negatively charged amino acid residues for an uncharged or positively charged amino acid residue is to make the charge of the human insulin analogue more negative at neutral pH and lower the isoelectric point vis a vis human insulin. Characteristically, the human insulin analogues of this invention have the same or a more negative charge (at neutral pH) and a lower isoelectric point than human insulin.

By and large, from 1 to 3 substitutions will achieve the immediate objectives of this invention, namely provide a more rapid action insulin, and such do constitute preferred modes of the invention. By using 2-3 substitutions an improved miscibility with protected insulin preparations may be achieved. However, it is believed advantageous that the immediate objectives of this invention can be achieved, also, through a greater number of substitutions than three, since desirable secondary objectives may be achieved thereby.

In particular, an additional level of substitution, say presence of 4 or 5 substitute amino acid residues, may result in a human insulin analogue that also is less subject to fibrillation, or interface polymerization, a characteristic particularly desirable when the insulin solution is intended for continuous infusion. By and large, not more than about 7 substitutions in the insulin molecule are contemplated for the human insulin analogue of this invention. Preferred are 2-4 substitutions.

DETAILED DESCRIPTION

Genes encoding the precursors of the present insulin analogues can be prepared by modification of genes encoding the above insulin precursors with formula (II) (or III) in which all X's are the amino acid residues of human insulin by site specific mutagenesis to insert or substitute with codons encoding the desired mutation. A DNA-sequence encoding the precursor of the insulin analogue may also be made by enzymatic synthesis from oligonucleotides corresponding in whole or part to the insulin analogue precursor gene.

DNA-sequences containing a gene with the desired mutation of the insulin gene are then combined with fragments coding for the TPI promoter (TPIp) (T. Alber and G. Kawasaki. Nucleotide Sequence of the Triose Phosphate Isomerase Gene of *Saccharomyces cerevisiae*. *J. Mol. Applied Genet.* 1 (1982) 419-434), the MF α 1 leader sequence (J. Kurjan and I. Herskowitz. Structure of a Yeast Pheromone Gene (MF α 1): A Putative α -Factor Precursor Contains four Tandem Copies of Mature α -Factor. *Cell* 30 (1982) 933-943) and the transcription termination sequence from TPI of *S. cerevisiae* (TPI τ). These fragments provide sequences to ensure a high rate of transcription for precursor encoding gene and also provide a presequence which can effect the localization of precursor into the secretory pathway and its eventual excretion into the growth medium. The expression units are furthermore provided with the yeast 2 μ origin of replication and a selectable marker, LEU 2.

During *in vivo* maturation of a α -factor in yeast, the last (C-terminal) six amino acids of the MF α 1 leader peptide (Lys-Arg-Glu-Ala-Glu-Ala) are removed from the α -factor precursor by the sequential action of an endopeptidase recognizing the Lys-Arg sequence and an aminodipeptidase which removes the Glu-Ala residues (Julius, D. et al. *Cell* 32 (1983) 839-852). To eliminate the need for the yeast aminodipeptidase, the sequence coding for the C-terminal Glu-Ala-Glu-Ala of the MF α 1 leader was removed from the MF α 1 leader sequence by *in vitro* mutagenesis. In the following text "MF α 1 leader" means the whole leader sequence whereas MF α 1 leader (minus Glu-Ala-Glu-Ala) means a leader sequence wherein the C-terminal Glu-Ala-Glu-Ala sequence has been removed.

Example 1

Construction of a synthetic gene encoding B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

5 A yeast codon optimized structural gene for B(1-29)-Ala-Ala-Lys-A(1-21) human insulin was constructed as follows.

The following 10 oligonucleotides were synthesized on an automatic DNA synthesizer using phosphoramidite chemistry on a controlled pore glass support (S.L. Beaucage and M.H. Caruthers (1981) *Tetrahedron Letters* 22, 1859-1869):

10

I:	AAAGATTCTTAACCAACACTTGTGCGGTTCCCAC
	35-mer
II:	AACCAAGTGGGAACCGCACAAGTGTGGTTACGAA
	36-mer
III:	TTGGTTGAAGCTTGTACTTGGTTGCGGTGAAAGAGGTTCT
	43-mer
IV:	GTAGAAGAACCTCTTCACCGCAAACCAAGTACAAAGCTTC
	42-mer
V:	TCTACACTCCTAAGGCTGCTAAGGGTATTGTC
	32-mer
VI:	ATTGTTGACAATACCCTAGCAGCCTTACCAAGT
	34-mer
VII:	GAACAATGCTGTACCTCCATCTGCTCCTGTACCAAT
	37-mer
VIII:	TTTTCCAATTGGTACAAGGAGCAGATGGAGGTACAGC
	37-mer
IX:	TGGAAAATCTGCAACTAGACGCAGCCGCAGGCT
	36-mer
X:	CTAGAGCCTGCGGGCTGCGTCTAGTTGCAGTAG
	33-mer

5 duplexes A-E were formed from the above 10 oligonucleotides as indicated on fig. 1.

45 20 pmole of each of the duplexes A-E was formed from the corresponding pairs of 5'-phosphorylated
 oligonucleotides I-X by heating for 5 min. at 90 °C followed by cooling to room temperature over a period of
 75 min. The 33-mer (X) in duplex E was not 5'-phosphorylated in order to avoid dimerization around the self
 complementary XbaI single stranded ends during the ligation. The synthetic five duplexes were mixed and
 treated with T4 ligase. The synthetic gene was isolated as a 182/183 bp band after electrophoresis of the
 50 ligation mixture on a 2% agarose gel.

The obtained synthetic gene is shown in fig. 1.

The synthetic gene was ligated to a 4 kb *Kpn*1-*Eco*R1 fragment and a 8 kb *Xba*1-*Kpn*1 fragment from pM7644 and a 0.3 kb *Eco*R1-*Hga*1 fragment from pKFN9 to give the following structure TPI_p-MF α 1 leader-B(1-29)-Ala-Ala-Lys-A(1-21)-TPI_t.

55 Plasmid pMT644 contains the DNA-sequence TPI_P-MFα1 leader-B(1-29)-A(1-21)-TPI_T and the construction is described in Danish patent specification No. 1293/85. The construction of plasmid pKFN9 is described in the following.

The ligation mixture was used to transform competent *E. coli* strain (r⁻,m⁺) (MT172). 30 ampicillin resistant colonies were transferred to plates containing minimal medium M9 (T. Maniatis et al., Molecular Cloning, Cold Spring Harbor Laboratory, 1982, p. 68) resulting in 8 Leu⁺ colonies. Maxam-Gilbert sequencing of a ³²P-Xba1-EcoR1 fragment showed that three plasmids contained a gene with the desired sequence. One plasmid pKFN27 was selected for further use.

5 The construction of pKFN27 is illustrated in fig. 2

Construction of plasmid pKFN9

10 The purpose of construction of plasmid pKFN9 was to obtain a plasmid containing a Hga1 site immediately after the MF α 1-leader sequence. Plasmid pMT544 (the construction of which is described in Danish patent specification No. 278/85) was cut with Xba1 and about 250 bases were removed from the 3'ends with ExoIII nuclease treatment. A synthetic 32-mer insertion primer GGATAAAAGAGGCGCGTCT-GAAGCTCACTC containing a Hga1 sequence was annealed to the partly single stranded DNA. A double 15 stranded circular DNA was made by filling in with Klenow polymerase and ligation with T4 ligase. After transformation of *E. coli* (r⁻,m⁺) (MT 172) colonies containing mutated plasmid were identified by colony hybridization with 5'-³²P-labelled 32-mer insertion primer. The occurrence of a new Hga1 site was confirmed with restriction enzyme cutting (EcoR1 + Hga1, Hind3 + Hga1). After retransformation a "pure" mutant pKFN9 was selected for further use. The construction of pKFN9 is illustrated in fig. 3.

20 Example 2

Preparation of B27Glu human insulin

25 B27Glu human insulin was prepared by transpeptidation of B27Glu,B(1-29)-Ala-Ala-Lys-A(1-21) human insulin with Thr-OBu¹ and acidolysis of the obtained threonine ester with trifluoroacetic acid. The preparation consisted of the following steps:

I. Construction of a gene encoding B27Glu, B(1-29)-Ala-Ala-Lys-A(1-21) insulin

30 Plasmid pKFN27 was linearized in the unique Xba1 site just downstream of the synthetic insulin precursor gene. In order not to destroy the Xba1 site by the filling in step described below a 19-mer Hind3-Xba1 double stranded linker

35

<u>Xba1</u>	<u>Hind3</u>
CTAGAAGAGCCCAAGACTA	
TTCTCGGGTTCTGATTCGA	

40

was ligated to each end of the linearized plasmid. The linker was 5'-phosphorylated at the Xba1 single stranded end but was left unphosphorylated at the Hind3 end, thereby avoiding polymerization of the linker during the ligation step and circularization of the DNA, see fig. 4.

45 5'-mononucleotides were removed from the 3'-ends of the obtained linear double stranded DNA by means of ExoIII nuclease treatment. The ExoIII nuclease treatment was performed at 23°C under conditions where about 250 nucleotides were removed from each 3'-end of the DNA (L. Guo and R. Wu (1983), Methods in Enzymology 100, 60-96).

50 A 5'-phosphorylated 25-mer mutagenesis primer d(GTTTCTTCTACGAACCTAAGGCTGC) was annealed to the mutation site. After filling in with Klenow polymerase in the presence of T4 ligase the double stranded DNA was digested with Xba1. Then heteroduplex circular DNA with the mutation in one strand was formed with T4 ligase.

The ligation mixture was transformed into *E. coli* (r⁻,m⁺) (MT172) selecting for ampicillin resistance.

Mutants were identified by colony hybridization with the 5'-32P-labelled 25-mer mutagenesis primer.

55 After retransformation plasmid pKFN37 from one of the resulting colonies was shown to contain the desired mutation by DNA sequencing of a 0.5 kb Xba1-EcoR1 fragment (A. Maxam and W. Gilbert (1980) Methods in Enzymology 65, 499-560).

II. Transformation

5 *S. cerevisiae* strain MT663 (E2-7B X E11-3C a/α, Δ tpi/Δ tpi, pep 4-3/pep 4-3) was grown on YPGaL (1% Bacto yeast extract, 2% Bacto peptone, 2% galactose, 1% lactate) to an OD_{600nm} of 0.6.

10 100 ml of culture was harvested by centrifugation, washed with 10 ml of water, re-centrifuged and resuspended in 10 ml of 1.2 M sorbitol, 25 mM Na₂EDTA pH = 8.0, 6.7 mg/ml dithiotreitol. The suspension was incubated at 30 °C for 15 minutes, centrifuged and the cells resuspended in 10 ml of 1.2 M sorbitol, 10 mM Na₂EDTA, 0.1 M sodium citrate pH = 5.8, 2 mg Novozym® 234. The suspension was incubated at 30 °C for 30 minutes, the cells collected by centrifugation, washed in 10 ml of 1.2 M sorbitol and in 10 ml of

15 CAS (1.2 M sorbitol, 10 mM CaCl₂, 10 mM Tris (Tris = Tris (hydroxymethyl)-aminometan) pH = 7.5) and resuspended in 2 ml of CAS. For transformation 0.1 ml of CAS-resuspended cells were mixed with approximately 1 μg of plasmid pKFN37 and left at room temperature for 15 minutes. 1 ml of 20% polyethyleneglycol 4000, 10 mM CaCl₂, 10 mM Tris pH = 7.5 was added and the mixture left for further 30 minutes at room temperature. The mixture was centrifuged and the pellet resuspended in 0.1 ml of SOS

20 (1.2 M sorbitol, 33% v/v YPGaL, 6.7 mM CaCl₂, 14 μg/ml leucine) and incubated at 30 °C for 2 hours. The suspension was then centrifuged and the pellet resuspended in 0.5 ml of 1.2 M sorbitol. 6 ml of top agar (the SC medium of Sherman et al., (Methods in Yeast Genetics, Cold Spring Harbor Laboratory, 1981) with leucine omitted and containing 1.2 M sorbitol plus 2.5% agar) at 52 °C was added and the suspension poured on top of plates containing the same agar-solidified, sorbitol containing medium. Transformant colonies were picked after 3 days at 30 °C, reisolated and used to start liquid cultures. One such transformant KFN40 (= MT663/pKFN37) was chosen for further characterization.

III. Expression of B27Glu, B(1-29)-Ala-Ala-Lys-A(1-21) insulin precursor

25 Yeast strain KFN40 was grown on YPD medium (1% yeast extract, 2% peptone, (both from Difco laboratories), and 2% glucose). A 10 ml culture of the strain was shaken at 30 °C to an OD₆₀₀ of 26. After centrifugation the supernatant was analyzed by reversed phase HPLC and 13.5 mg/l precursor was found.

30 The analogue in the supernatant was concentrated on a cation exchange column at low pH followed by desorption with a suitable buffer solution. Crystallization was performed with an alcoholic citrate buffer.

IV. Transpeptidation

35 0.2 mole (47.1 g) Thr-OBu^t, HOAC was dissolved in DMF to give 100 ml solution, 50 ml 76.5% v/v DMF in water was added and 10 g of crude B27Glu, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin was dissolved in the mixture, which was thermostated at 12 °C. Then 1 g of trypsin in 25 ml 0.05 M calcium acetate was added and after 24 h at 12 °C the mixture was added to 2 liter of acetone and the precipitated peptides were isolated by centrifugation and dried in vacuo. The B27Glu, B30Thr-OBu^t human insulin was purified on a preparative HPLC column with silica-C18 as column material.

V. Conversion into B27 human insulin

40 The B27Glu, B30Thr-OBu^t human insulin was dissolved in 100 ml triflour acetic acid. After 2 hours at room temperature the solution was lyophilized. The lyophilized powder was dissolved in 400 ml 47.5 mM sodium citrate at pH 7. The peptides were precipitated at pH 5.5 after addition of 2.4 ml 1 M ZnCl₂, isolated by centrifugation and dried in vacuo. The product was purified by anion exchange chromatography and desalted by gel filtration. Yield: 1.7 g of B27Glu human insulin.

Example 350 Preparation of B9Asp human insulin

B9Asp human insulin was prepared by transpeptidation of B9Asp, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin with Thr-OBu^t and acidolysis of the obtained threonine ester with triflour acetic acid.

55 I. Construction of a gene encoding B9Asp, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

This gene was constructed in the same manner as described for the gene encoding B27Glu, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin by site specific mutagenesis of pKFN27 directed by a 23-mer

mutagenesis primer d(CTTGTGCGGTGACCACTTGGTTG). Plasmid pKFN38 was shown to contain the desired mutation.

II. Transformation

5

Plasmid pKFN38 was transformed into *S. cerevisiae* strain MT663 by the same procedure as in example 2, II and a transformant KFN41 was isolated.

III. Expression of B9Asp, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

10

Yeast strain KFN41 was grown on YPD medium as described in example 2, III. 2.5 mg/l of the insulin analogue precursor was found in the supernatant.

IV. Transpeptidation

15

7.4 g of crude B9Asp, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin was transpeptidated as described in example 2, IV to give B9Asp, B30Thr-OBu^t human insulin.

V. Conversion

20

The B9Asp, B30Thr-OBu^t human insulin was converted into B9Asp human insulin as described in example 2, V. Yield: 0.83 g B9Asp human insulin.

Example 4

25

Preparation of B9Asp, B27Glu human insulin

B9Asp, B27Glu human insulin was prepared by transpeptidation of B9Asp, B27Glu B(1-21)-Ala-Ala-Lys-A(1-21) human insulin with Thr-OBu^t and acidolysis of the obtained threonine ester with trifluor acetic acid.

30

I. Construction of a gene encoding B9Asp, B27Glu, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

A 367 bp EcoR1-Hind3 fragment from pKFN38 (see example 3) and a 140 bp Hind3-Xba1 fragment from pKFN37 (see example 2) were ligated to the large Xba1-EcoR1 fragment of plasmid pUC13 (this plasmid was constructed as described for pUC8 and pUC9 by Vieira et al. (1982), Gene 19, 259-268). The ligation mixture was transformed into *E. coli* (MT 172) selecting for ampicillin resistance. Plasmids were prepared from a number of transformants and analyzed by digestion with Pst1 and with Hind3. The 0.5 kb Xba1-EcoR1 fragment from one plasmid, which showed the correct restriction enzyme patterns, was ligated to a 7.8 kb Xba1-Kpn1 fragment and a 4.3 kb Kpn1-EcoR1 fragment both from pMT644 (described in 35 Danish patent application No.1293/84). The ligation mixture was transformed into *E. coli* (MT172) selecting for ampicillin resistance. Plasmid pKFN43 from one of the resulting colonies was shown to contain the gene for the desired insulin derivative precursor by DNA sequencing of a 0.5 kb Xba1-EcoR1 fragment. The 40 construction of pKFN43 is illustrated in fig. 5

45 II. Transformation

Plasmid pKFN38 was transformed into *S. cerevisiae* strain MT663 by the same procedure as in example 2, II and a transformant KFN44 was isolated.

50

III. Expression of B9Asp, B27Glu, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

Yeast strain KFN44 was grown on YPD medium as described in example 2, III. 7.3 mg/l of the insulin analogue precursor was found in the supernatant.

55

IV. Transpeptidation

12.7 g of crude B9Asp, B27Glu, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin was transpeptidated as described in example 2, IV to give B9Asp, B27Glu, B30Thr-OBu^t human insulin.

V. Conversion

The B9Asp,B27Glu,B30Thr-OBu¹ human insulin was converted into B9Asp,B27Glu,B30Thr human insulin and purified as described in example 2, V. Yield: 1.0 g B9Asp,B27Glu human insulin.

5

Example 5Preparation of A8His,B9Asp,B27Glu human insulin

10 A8His, B9Asp,B27Glu human insulin was prepared by transpeptidation of A8His,B9Asp,B27Glu, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin with Thr-OBu¹ and acidolysis of the obtained threonine ester with trifluor acetic acid as described in example 2.

I. Construction of a gene encoding A8His,B9Asp,B27Glu, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

15

This gene was constructed by oligonucleotide directed mutagenesis using a gapped duplex procedure (Y. Morinaga, T. Franceschini, S. Inouye, and M. Inouye (1984), Biotechnology 2, 636-639). The pUC13 derived plasmid encoding the MF α 1 leader sequence and the B9Asp,B27Glu human insulin precursor (fig. 5) was cut with HpaI and XbaI. The large fragment was mixed with the plasmid linearized with NdeI. After 20 heat denaturation and cooling the mixture contains gapped duplexes with a single stranded "window" in the region corresponding to the insulin precursor gene (HpaI-XbaI). The 37-mer mutagenic mismatch primer d-(GAACAATGCTGTCACTCCATCTGCTCCTTGTACCAAT) was hybridized to the gapped duplex followed by filling in with Klenow polymerase and ligation. The mixture was used to transform E. coli (MT172) selecting for ampicillin resistance. Mutants were identified by colony hybridization with an 18-mer 5'-³²P-labelled probe d(AATGCTGTCACTCCATCT). After retransformation a plasmid from one of the resulting colonies was shown to contain the desired mutation by DNA sequencing of a 0.5 kb XbaI-EcoRI fragment. This plasmid was used for construction of the yeast plasmid pKFN 102 as described in example 4 for the construction of pKFN43.

30 II. Transformation

Plasmid pKFN102 was transformed into S. cerevisiae strain MT663 by the same procedure as in example 2, II and a transformant KFN109 was isolated.

35 III. Expression of A8His,B9Asp,B27Glu, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

Yeast strain KFN109 was grown on YPD medium as described in example 2, III. 21.5 mg/l of the insulin analogue precursor was found in the supernatant.

40 IV-V. Transpeptidation and conversion

22.0 g crude A8His,B9Asp,B27Glu, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin was transpeptidated, converted and purified as described in example 2, IV-V. Yield: 4.0 g A8HisB9AspB27Glu human insulin.

45 Example 6Preparation of B12Ile human insulin

B12Ile human insulin was prepared by transpeptidation of B12Ile, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin with Thr-OBu¹ and acidolysis of the obtained threonine ester with trifluor acetic acid as described in example 2.

I. Construction of a gene encoding B12Ile, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

55 A 0.5 kb EcoR1-XbaI fragment of pMT598 (the construction of plasmid pMT598 is described in EP patent application No. 0163529A) encoding MF α 1 leader (minus Glu-Ala-Glu-Ala)-B(1-29)-Ala-Ala-Lys-A(1-21) was inserted into M13 mp10 RF phage cut with XbaI-EcoRI and the corresponding single strand DNA was purified from the M13 mp10 recombinant phage. The single strand template DNA was hybridized to a

mutagenic 27 mer primer NOR-92 d(GTAGAGAGCTTCGATCAGGTGTGAGCC) and a M13 universal sequencing primer d(TCCCAGTCACGACGT). The primers were extended by dNTPs and Klenow polymerase and ligated by T4 DNA ligase. The mutagenic primer KFN92 was chosen so as to destroy a BstN1 site (unique in the Xba1-EcoR1 fragment). Therefore, to select against unmutated EcoR1-Xba1 fragment, 5 the mixture was cut with BstN1 and subsequently with EcoR1 and Xba1, and ligated to EcoR1 and Xba1 cut pUC13 vector. From one of the transformants obtained, a plasmid, pMT760, lacking the BstN1 site in the insulin coding sequence was chosen. The desired mutated sequence was verified by Maxam-Gilbert DNA sequencing. Plasmid pMT760 contains a 0.5 kb EcoR1-Xba1 sequence corresponding to the same fragment 10 from pMT598 (see above) apart from a mutation at B12 (Val - Ile). This mutated sequence was then moved onto a yeast expression plasmid by ligation of the 0.5 kb EcoR1-Xba1 fragment of pMT760 to a 7.8 kb Xba1-Kpn1 and a 4.3 kb Kpn1-EcoR1 fragment from pMT644 to give pMTA.

II-V. Transformation, Expression, Transpeptidation, Conversion

15 Plasmid pMTA was transformed into yeast strain MT663 as described in example 2, II and the transformant strain MTA was grown as described in example 2, III. 10.4 mg/l of the insulin analogue precursor was found in the supernatant. 10 g of the crude analogue precursor was transpeptidated, converted and purified as described in example 2, IV-V. Yield: 1.3 g of B12Ile human insulin.

20 Example 7

Preparation of B12Tyr human insulin.

25 B12Tyr, human insulin can be prepared by transpeptidation of B12Tyr, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin with Thr-OBu^t and acidolysis of the obtained threonine ester with trifluor acetic acid as described in example 2.

I. Construction of a gene encoding B12Tyr, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

30 The gene was constructed by a method analogue to the method for the preparation of the gene encoding B12Ile, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin with the only exception that primer KFN93 d-(GTAGAGAGCTTCGTACAGGTGTGAGCC) was used instead of KFN92.

II-IV. Transformation, Expression, Transpeptidation, Conversion.

35 Steps II - III were performed as described in example 2. 1.7 mg/l of the insulin analogue precursor was found in the supernatant. The crude analogue precursor can be transpeptidated, converted and purified as described in example 2, VI-V to give B12Tyr human insulin.

40 Example 8

Preparation of B10Asp human insulin

45 B10 Asp human insulin was prepared by transpeptidation of B10Asp, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin with Thr-OBu^t and acidolysis of the obtained threonine ester with trifluor acetic acid as described in example 2.

I. Construction of a gene encoding B10Asp, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

50 The gene was constructed by a method analogue to the method for the preparation of the gene encoding B12Ile, (B(1-29)-Ala-Ala-Lys-A(1-21) human insulin with the only exception that primer KFN94 d-(AGCTTCCACCAGATCTGAGCCGCACAG) was used instead of KFN92.

II-V. Transformation, Expression, Transpeptidation, Conversion

55 Steps II-III were performed as described in example 2. 36 mg/l of the insulin analogue precursor was found in the supernatant. The crude analogue precursor was transpeptidated, converted and purified as described in example 2, IV-V. Yield: 7.6 g of B10Asp human insulin.

Example 9Preparation of B28Asp human insulin

5 B28Asp human insulin was prepared by transpeptidation of B28Asp, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin with Thr-OMe and hydrolysis of the obtained threonine ester at a pH of about 8 to 12.

I. Construction of a gene encoding B28Asp, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

10 A 0.5 kb EcoR1-Xba1 fragment of pMT 462 (the construction of plasmid pMT 462 is described in Danish patent application No. 1257/86) encoding the MF α 1 leader (minus Glu-Ala-Glu-Ala)-B-C-A, i.e. the human proinsulin gene preceded by the modified MF α 1 leader, was inserted into M13 mp10 RF phage cut with Xba1-EcoR1 and the corresponding single strand DNA was purified from the M13 mp10 recombinant phage. The single strand template DNA was hybridized to a mutagenic 41 mer primer NOR205 d-(TTCCACAATGCCCTTAGCGGCCTTGTGTAGAAGAAGC) and a M13 universal sequencing primer d-(TCCCAGTCACGACGT). The primers were extended by dNTPs and Klenow polymerase and ligated by T4 DNA ligase.

15 After phenol extraction, ethanol precipitation and resuspension, the DNA was cut with restriction enzymes Apa 1, Xba1 and EcoR1. After another phenol extraction, ethonal precipitation and resuspension, the DNA was ligated to EcoR1-Xba1 cut pUC13. The ligation mixture was transformed into an *E. coli* (r^m) strain and plasmids were prepared from a number of transformants. Plasmid preparations were cut with EcoR1 and Xba1 and those preparations showing bands at both 0.5 and 0.6 kb were retransformed into *E. coli*. From the retransformation a transformant harbouring only pU13 with a 0.5 insert was selected.

20 From one of the transformants obtained a plasmid pMT881 with the desired mutation at B28 (Pro → Asp) was chosen. The mutated sequence was verified by Maxam-Gilbert DNA sequencing. The mutated sequence was then moved onto a yeast expression plasmid by ligation of a 0.5 kb EcoR1-Xba1 fragment of pMT881 to a 7.8 kb Xba1-Kpn1 and a 4.3 kb Kpn1-EcoR1 fragment from pMT644 to give pMTA1.

II. Transformation

30 Plasmid pMTA1 was transformed into *S. cerevisiae* strain MT663 by the same procedure as in example 2, II and a transformant MTA1 was isolated.

III. Expression of B28Asp, B(1-29)-Ala-Ala-Lys-A(1-21) human insulin

35 Yeast strain MTA1 was grown on YPD medium as described in example 2, III. 7.2 mg/l of the insulin analogue precursor was found in the supernatant.

IV. Transpeptidation

40 The crude B28Asp,B(1-29)-Ala-Ala-Lys-A(1-21) was transpeptidated as described in example 2, IV by substituting Thr-OBu^t with Thre-OMe to give B28Asp, B30Thr-OMe human insulin.

V. Conversion

45 The B28Asp,B30Thr-OMe human insulin was dispersed in water to 1% (w/v) and was dissolved by addition of 1N sodium hydroxide to a pH value of 10.0. The pH value was kept constant at 10.0 for 24 hours at 25 °C. The B28Asp human insulin formed was precipitated by addition of sodium chloride to about 8% (w/v), sodium acetate trihydrate to about 1.4% (w/v), and zinc acetate dihydrate to about 0.01% (w/v) followed by addition of 1N hydrochloric acid to pH 5.5. The precipitate was isolated by centrifugation and purified by anion exchange chromatography and desalting by gel filtration. Yield: 0.2 g B28Asp human insulin.

Example 10Preparation of A21Asp,B9Asp,B27Glu human insulin

5 A21Asp, B9Asp, B27Glu human insulin was prepared from B9Asp, B27Glu human insulin by selective deamidation (hydrolysis of a 5% solution for 14 days at 37°C, pH 2.5). The deamidated product was isolated by anion exchange chromatography.

Example 11Preparation of B27Glu,A21Asp human insulin

10 B27Glu,A21Asp human insulin was prepared by transpeptidation of B27Glu,A21Asp,B(1-29)-Ala-Ala-Lys-A(1-21) with ThrOBu^t and acidolysis of the obtained threonine ester with trifluor acetic acid as described in example 2.

15 B27GluA21AspB(1-29)-Ala-Ala-Lys-A(1-21) was prepared from B27Glu,B(1-29)-Ala-Ala-Lys-A(1-21) (see example 2) by deamidation as described in example 10.

Characterization of human insulin analogue of the present invention

20 Determination of molecular weights (Gutfreund H. Biochemical Journal 42 (544) 1948).

Method: Knauer Membran Osmometer
 Type: 1.00
 Membran: Schleicher and Schüll
 25 Type: R52
 Solvent: 0.05 M NaCl pH 7.5
 Temp.: 21 °C
 Results: All types of insulin were measured at a concentration of 4 mg/ml

30 **Table 1**

Type of insulin	Molecular weight k Dalton
Human 2Zn insulin	36 ± 2
Human Zn free insulin	29 ± 1
Zn free B27Glu human insulin	22 ± 1
40 - - B12Ile human insulin	17 ± 1
- - B27Glu,A21Asp human insulin	8 ± 1
- - B9Asp,B27Glu human insulin	6 ± 1
45 - - B9Asp human insulin	6 ± 1
- - B9Asp,B27Glu,A21Asp human insulin	6 ± 1
- - B9Asp,B27Glu,A8His human insulin	9 ± 3
- - B10Asp human insulin	12 ± 1
50 - - B28Asp human insulin	9 ± 2

It appears from the above table 1 that the human insulin analogues have a markedly reduced molecular weight compared with human insulin meaning that the self-associating into dimers, tetramers and hexamers is less pronounced or in several cases even lacking.

Table 2

Half life and Biological potency			
	Human insulin analogue	T _{1/2} * (% of human insulin)	Biological potency** % of human insulin (95% conf. interval)
5	B27Glu human insulin	78	101 (83-123)
10	B9Asp,B27Glu human insulin	54	110 (90-139)
15	B12Ile human insulin	78	91 (80-103)
20	B27Glu,A21Asp human insulin	56	64 (58-71)
25	B9Asp human insulin	52	80 (72-90)
30	A21Asp,B9Asp,B27Glu human insulin	56	75 (66-85)
35	A8His,B9Asp,B27Glu human insulin	68	116 (101-135)
40	B10Asp human insulin	64	104 (92-118)
45	B28Asp human insulin		104 (95-114)

* Time to 50% disappearance from injection site (subcut.) in pigs. Method according to Binder 1969 (Acta Pharmacol. Toxicol (suppl 2) 27:1-87)

** Mouse Blood Glucose Assay according to European Pharmacopocia.


It appears from the above table 2 that the time to 50% disappearance of the insulin analogues from the injection site is substantially reduced when compared with human insulin.

The biological potency of the insulin analogues is comparable with human insulin or only slightly reduced.

Claims

Claims for the following Contracting States : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Rapid acting human insulin analogues, characterized in that they have the formula I



wherein at least one but not more than seven of the X's are the same or different amino acid residue substitutions, the net function of which is to impart to the molecule the same charge or a greater negative charge at neutral pH than that of human insulin, the remaining X's being the natural amino acid residues of human insulin at the respective position in the insulin molecule, with the proviso that there is at least one substitution in the B-chain and that when X in position B(5) is Ala, X in position B(9) is Leu, X in position B(10) is Asn or Leu, X in position B(12) is Asn or X in position B(26) is Ala, then at least one of the remaining X's are different from the amino acid residues of human insulin at the respective position in the insulin molecule and with the further proviso that X in position B(5) can not be Asp and X in position B(12) can not be Glu, and wherein one or more amino acid residues may have been removed from the N- and/or C-terminal ends of the A- and/or B-chain, with the additional proviso that, when X is Ala in one or more of positions B(1), B(2), B(5), B(9), B(10), B(27) or B(28), then at least one of any of the X's, except any X which is Ala in position B(1), B(2), B(5), B(9), B(10), B(27) and/or B(28), is different from the amino acid residues of human insulin at the respective position in the insulin

molecule.


2. Insulin analogues according to claim 1, wherein the amino acid residue substitutions are more hydrophilic than the amino acid residue of human insulin at the respective position in the insulin molecule.
5
3. Human insulin analogues according to claim 1, wherein the amino acid substitutions are selected from the group consisting of Asp, Glu, Ser, Thr, His, and Ile.
10
4. Human insulin analogues according to claim 1, wherein the amino acid residue substitutions are Asp and/or Glu.
15
5. Human insulin analogues according to claim 1, wherein at least one X in position B(9), B(10), B(12), B-(26), B(27), or B(28) is different from the amino acid residue at the corresponding site in the molecule of human insulin.
20
6. Human insulin analogues according to claim 1, wherein at least one X in position B(9), B(12), B(27), or B(28) is different from the amino acid residue at the corresponding site in the molecule of human insulin.
25
7. Human insulin analogue according to claim 1, wherein X in position B27 is Glu, X in position B12 is Ile, or Tyr, X in position A21 is Asp and position B27 is Glu, X in position B9 is Asp, X in position A21 and in position B9 is Asp and in position B27 is Glu, X in position A8 is His, in position B9 is Asp and in position B27 is Glu, X in position B10 is Asp, X in position B9 is Asp and in position B27 is Glu, or X in position B28 is Asp.
30
8. Human insulin analogues according to claim 1, characterized in that they lack up to four amino acid residues at the N-terminal of the B-chain and/or up to five amino acid residues at the C-terminal end of the B-chain.
35
9. Human insulin analogues according to claim 8, characterized in that they lack the B(1)-amino acid residue and/or the B(30)-amino acid residue.
40
10. A method for the preparation of human insulin analogues according to claim 1, wherein a yeast strain containing a replicable expression vehicle comprising a DNA-sequence encoding a precursor of the insulin analogue is cultured in a suitable nutrient medium, and the precursor is recovered from the culture medium and converted into the novel insulin analogue by enzymatic and chemical in vitro conversion.
45
11. A method for the preparation of human insulin analogues according to claim 1, wherein a biosynthetic precursor of the general formula II

45

50

55

A - chain



II


B - chain

20 wherein Q_n is a peptide chain with n naturally occurring amino acid residues, R is Lys or Arg, n is an integer from 0 to 33, m is 0 or 1, and the X 's are defined as above with the proviso that the peptide chain $-Q_n-R-$ does not contain two adjacent basic amino acid residues is reacted with an L-threonine ester in the presence of trypsin or a trypsin derivative followed by conversion of the obtained threonine ester of the human insulin analogue into the human insulin analogue by known methods.

25

12. A method for the production of human insulin analogues according to claim 1, wherein a biosynthetic precursor of the general formula III

30 A - chain



III

45 B - chain


50 wherein V and T are each Lys or Arg and the X 's are defined as above, are reacted with trypsin and carboxypeptidase B in aqueous solution and the human insulin analogue is recovered from the reaction mixture.

55 13. A process for the preparation of human insulin analogues according to claim 1, wherein the insulin analogues containing the appropriate amino acid substitutions are synthesized chemically according to known methods, or A- and B-chains containing the appropriate amino acid substitution are synthesized chemically according to known methods and the modified A- and B-chains are linked together by establishing disulphide bridges between A(7)Cys and B(7)Cys, and between A(20)Cys and B(19)Cys and the internal A-chain bridge between A(6)Cys and A(11)Cys.

14. Injectable solutions with insulin activity, characterized in that they contain a human insulin analogue according to claim 1 or a pharmaceutically acceptable salt thereof in aqueous solution, preferably at neutral pH.


5 Claims for the following Contracting State : AT

1. A method for the preparation of human insulin analogues of the formula I




25 wherein at least one but not more than seven of the X's are the same or different amino acid residue substitutions, the net function of which is to impart to the molecule the same charge or a greater negative charge at neutral pH than that of human insulin, the remaining X's being the natural amino acid residues of human insulin at the respective position in the insulin molecule, with the proviso that there is at least one substitution in the B-chain and that when X in position B(5) is Ala, X in position B-
 30 (9) is Leu, X in position B(10) is Asn or Leu, X in position B(12) is Asn or X in position B(26) is Ala, then at least one of the remaining X's are different from the amino acid residues of human insulin at the respective position in the insulin molecule and with the further proviso that X in position B(5) can not be Asp and X in position B(12) cannot be Glu, and wherein one or more amino acid residues may have been removed from the N- and/or C-terminal ends of the A- and/or B-chain, with the additional proviso that, when X is Ala in one or more of positions B(1), B(2), B(5), B(9), B(10), B(27) or B(28), then at least one of any of the X's, except any X which is Ala in position B(1), B(2), B(5), B(9), B(10), B(27) and/or B-
 35 (28), is different from the amino acid residues of human insulin at the respective position in the insulin molecule, wherein a yeast strain containing a replicable expression vehicle comprising a DNA-sequence encoding a precursor of the insulin analogue is cultured in a suitable nutrient medium, and the precursor is recovered from the culture medium and converted into the novel insulin analogue by
 40 enzymatic and chemical in vitro conversion.

2. A method for the preparation of human insulin analogues of the formula I



wherein at least one but not more than seven of the X's are the same or different amino acid residue substitutions, the net function of which is to impart to the molecule the same charge or a greater negative charge at neutral pH than that of human insulin, the remaining X's being the natural amino acid residues of human insulin at the respective position in the insulin molecule, with the proviso that there is at least one substitution in the B-chain and that when X in position B(5) is Ala, X in position B(9) is Leu, X in position B(10) is Asn or Leu, X in position B(12) is Asn or X in position B(26) is Ala, then at least one of the remaining X's are different from the amino acid residues of human insulin at the respective position in the insulin molecule and with the further proviso that X in position B(5) can not be Asp and X in position B(12) can not be Glu, and wherein one or more amino acid residues may have been removed from the N- and/or C-terminal ends of the A- and/or B-chain, with the additional proviso that, when X is Ala in one or more of positions B(1), B(2), B(5), B(9), B(10), B(27) or B(28), then at least one of any of the X's, except any X which is Ala in position B(1), B(2), B(5), B(9), B(10), B(27) and/or B(28), is different from the amino acid residues of human insulin at the respective position in the insulin molecule, wherein a biosynthetic precursor of the general formula II


A-chain



B - chain


35 wherein Q_n is a peptide chain with n naturally occurring amino acid residues, R is Lys or Arg, n is an integer from 0 to 33, m is 0 or 1, and the X 's are defined as above with the proviso that the peptide chain $-Q_n-R-$ does not contain two adjacent basic amino acid residues is reacted with an L-threonine ester in the presence of trypsin or a trypsin derivative followed by conversion of the obtained threonine ester of the human insulin analogue into the human insulin analogue.
40

3. A method for the production of human insulin analogues of the formula I



wherein at least one but not more than seven of the X's are the same or different amino acid residue substitutions, the net function of which is to impart to the molecule the same charge or a greater negative charge at neutral pH than that of human insulin, the remaining X's being the natural amino acid residues of human insulin at the respective ion in the insulin molecule, with the proviso that there is at least one substitution in the B-chain and that when X in position B(5) is Ala, X in position B(9) is Leu, X in position B(10) is Asn or Leu, X in position B(12) is Asn or X in position B(26) is Ala, then at least one of the remaining X's are different from the amino acid residues of human insulin at the respective position in the insulin molecule and with the further proviso that X in position B(5) can not be Asp and X in position B(12) can not be Glu, and wherein one or more amino acid residues may have been removed from the N- and/or C-terminal ends of the A- and/or B-chain, with the additional proviso that, when X is Ala in one or more of positions B(1), B(2), B(5), B(9), B(10), B(27) or B(28), then at least one of any of the X's, except any X which is Ala in position B(1), B(2), B(5), B(9), B(10), B(27) and/or B(28), is different from the amino acid residues of human insulin at the respective position in the insulin molecule, wherein a biosynthetic precursor of the general formula III

15

A - chain


III

B - chain

35

wherein V and T are each Lys or Arg and the X's are defined as above, are reacted with trypsin and carboxypeptidase B in aqueous solution and the human insulin analogue is recovered from the reaction mixture.

40 4. A process for the preparation of human insulin analogues of the formula I

A - chain

I

B - chain

wherein at least one but not more than seven of the X's are the same or different amino acid residue

substitutions, the net function of which is to impart to the molecule the same charge or a greater negative charge at neutral pH than that of human insulin, the remaining X's being the natural amino acid residues of human insulin at the respective position in the insulin molecule with the proviso that there is at least one substitution in the B-chain and that when X in position B(5) is Ala, X in position B-
5 (9) is Leu, X in position B(10) is Asn or Leu, X in position B(12) is Asn or X in position B(26) is Ala, then at least one of the remaining X's are different from the amino acid residues of human insulin at the
10 respective position in the insulin molecule and with the further proviso that X in position B(5) can not be Asp and X in position B(12) can not be Glu, and wherein one or more amino acid residues may have been removed from the N- and/or C-terminal ends of the A- and/or B-chain, with the additional proviso
15 that, when X is Ala in one or more of positions B(1), B(2), B(5), B(9), B(10), B(27) or B(28), then at least one of any of the X's, except any X which is Ala in position B(1), B(2), B(5), B(9), B(10), B(27) and/or B-
20 (28), is different from the amino acid residues of human insulin at the respective position in the insulin molecule, wherein the insulin analogues containing the appropriate amino acid substitutions are synthesized chemically according to known methods, or A- and B-chains containing the appropriate
25 amino acid substitution are synthesized chemically according to known methods and the modified A- and B-chains are linked together by establishing disulphide bridges between A(7)Cys and B(7)Cys, and between A(20)Cys and B(19)Cys and the internal A-chain bridge between A(6)Cys and A(11)Cys.

5. A method according to any one of Claims 1 to 4, wherein the amino acid residue substitutions in the insulin analogue prepared are more hydrophilic than the amino acid residue of human insulin at the respective position in the insulin molecule.
6. A method according to any one of Claims 1 to 5, wherein the amino acid substitutions in the insulin analogue prepared are selected from the group consisting of Asp, Glu, Ser, Thr, His, and Ile.
7. A method according to Claim 6, wherein the amino acid residue substitutions are Asp and/or Glu.
8. A method according to any one of Claims 1 to 7, wherein at least one X in position B(9), B(10), B(12), B(26), or B(27) of the insulin analogue prepared is different from the amino acid residue at the corresponding site in the molecule of human insulin.
9. A method according to Claim 8, wherein at least one X in position B(9), B(12), B(27) or B(28) is different from the amino acid residue at the corresponding site in the molecule of human insulin.
- 30 10. A method according to any one of Claims 1 to 4, wherein, in the insulin analogue prepared, X in position B27 is Glu, X in position B12 is Ile, or Tyr, X in position A21 is Asp and position B27 is Glu, X in position B9 is Asp, X in position A21 and in position B9 is Asp and in position B27 is Glu, X in position A8 is His, in position B9 is Asp and in position B27 is Glu, X in position B10 is Asp, X in position B9 is Asp and in position B27 is Glu, or X in position B28 is Asp.
- 35 11. A method according to any one of Claims 1 to 4, wherein the insulin analogue prepared lacks up to four amino acid residues at the N-terminal of the B-chain and/or up to five amino acid residues at the C-terminal end of the B-chain.
- 40 12. A method according to Claim 2, wherein the insulin analogue prepared lacks the B(1)-amino acid residue and/or the B(30)-amino acid residue.


Patentansprüche

Patentansprüche für folgende Vertragsstaaten : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Schnellwirkende Analoga von Humaninsulin, dadurch gekennzeichnet, daß sie die Formel I besitzen

5

A-Kette



worin wenigstens ein, aber nicht mehr als sieben der Xe dieselben oder verschiedene Aminosäurerestsubstitutionen sind, deren Nettofunktion es ist, dem Molekül dieselbe Ladung oder eine größere negative Ladung bei neutralem pH als diejenige von Humaninsulin zu verleihen, wobei die restlichen Xe die natürlichen Aminosäurereste von Humaninsulin an der entsprechenden Position im Insulin-Molekül sind, mit der Maßgabe, daß es wenigstens eine Substitution in der B-Kette gibt und daß, wenn X in Position B(5) Ala ist, X in Position B(9) Leu ist, X in Position B(10) Asn oder Leu ist, X in Position B(12) Asn ist oder X in Position B(26) Ala ist, dann wenigstens eines der restlichen Xe verschieden ist von den Aminosäureresten von Humaninsulin an der entsprechenden Position im Insulin-Molekül, und mit der weiteren Maßgabe, daß X in Position B(5) nicht Asp sein kann und X in Position B(12) nicht Glu sein kann, und wobei ein oder mehrere Aminosäurereste von den N- und/oder C-terminalen Enden der A- und/oder B-Kette entfernt worden sein können, mit der zusätzlichen Maßgabe, daß, wenn X in einer oder mehreren der Positionen B(1), B(2), B(5), B(9), B(10), B(27) oder B(28) Ala ist, dann wenigstens eines von allen Xen, mit Ausnahme von jedem X, das in Position B(1), B(2), B(5), B(9), B(10), B(27) und/oder B(28) Ala ist, verschieden ist von den Aminosäureresten von Humaninsulin an der entsprechenden Position im Insulin-Molekül.

40 2. Analoga von Insulin nach Anspruch 1, wobei die Aminosäurerestsubstitutionen hydrophiler sind als der Aminosäurerest von Humaninsulin an der entsprechenden Position im Insulin-Molekül.

3. Analoga von Humaninsulin nach Anspruch 1, wobei die Aminosäuresubstitutionen ausgewählt sind aus der Gruppe, die aus Asp, Glu, Ser, Thr, His und Ile besteht.

45 4. Analoga von Humaninsulin nach Anspruch 1, wobei die Aminosäurerestsubstitutionen Asp und/oder Glu sind.

50 5. Analoga von Humaninsulin nach Anspruch 1, wobei wenigstens ein X in Position B(9), B(10), B(12), B-(26), B(27) oder B(28) verschieden ist von dem Aminosäurerest an der entsprechenden Stelle im Molekül von Humaninsulin.

6. Analoga von Humaninsulin nach Anspruch 1, wobei wenigstens ein X in Position B(9), B(12), B(27) oder B(28) verschieden ist von dem Aminosäurerest an der entsprechenden Stelle im Molekül von Humaninsulin.


55 7. Analog von Humaninsulin nach Anspruch 1, wobei X in Position B27 Glu ist, X in Position B12 Ile oder Tyr ist, X in Position A21 Asp ist und in Position B27 Glu ist, X in Position B9 Asp ist, X in Position A21 und in Position B9 Asp und in Position B27 Glu ist, X in Position A8 His ist, in Position B9 Asp ist und

in Position B27 Glu ist, X in Position B10 Asp ist, X in Position B9 Asp ist und in Position B27 Glu ist oder X in Position B28 Asp ist.

8. Analoga von Humaninsulin nach Anspruch 1, dadurch gekennzeichnet, daß ihnen bis zu vier Aminosäurereste am N-Terminus der B-Kette und/oder bis zu fünf Aminosäurereste am C-terminalen Ende der B-Kette fehlen.
9. Analoga von Humaninsulin nach Anspruch 8, dadurch gekennzeichnet, daß ihnen der B(1)-Aminosäurerest und/oder der B(30)-Aminosäurerest fehlt.
10. Ein Verfahren zur Herstellung von Analoga von Humaninsulin nach Anspruch 1, wobei ein Hefestamm, der ein replizierbares Expressionsvehikel enthält, das eine DNA-Sequenz umfaßt, die einen Vorläufer des Analogs von Insulin kodiert, in einem geeigneten Nährstoffmedium kultiviert wird und der Vorläufer aus dem Kulturmedium gewonnen und in das neuartige Analog von Insulin durch enzymatische und chemische in-vitro-Umwandlung umgewandelt wird.
11. Ein Verfahren zur Herstellung von Analoga von Humaninsulin nach Anspruch 1, wobei ein biosynthetischer Vorläufer der allgemeinen Formel II

20

A-Kette




40

B-Kette

- 45 worin Q_n eine Peptidkette mit n natürlich auftretenden Aminosäureresten ist, R Lys oder Arg ist, n eine ganze Zahl von 0 bis 33 ist, m 0 oder 1 ist und die Xe wie oben definiert sind, mit der Maßgabe, daß die Peptidkette - Q_n -R-nicht zwei benachbarte basische Aminosäureresten enthält, mit einem L-Threoninester in der Gegenwart von Trypsin oder einem Trypsin-Derivat zur Reaktion gebracht wird, gefolgt von der Umwandlung des erhaltenen Threoninesters des Analogs von Humaninsulin in das Analog von Humaninsulin mit bekannten Verfahren.
- 50
12. Ein Verfahren zur Herstellung von Analoga von Humaninsulin nach Anspruch 1, wobei ein biosynthetischer Vorläufer der allgemeinen Formel III

55

A-Kette



20

B-Kette

25 worin V und T jeweils Lys oder Arg sind und die Xe wie oben definiert sind, mit Trypsin und Carboxypeptidase B in wäßriger Lösung zur Reaktion gebracht wird und das Analog von Humaninsulin aus der Reaktionsmischung gewonnen wird.

30 13. Ein Verfahren zur Herstellung von Analoga von Humaninsulin nach Anspruch 1, wobei die Analoga von Insulin, die die geeigneten Aminosäuresubstitutionen enthalten, gemäß bekannten Verfahren chemisch synthetisiert werden oder A- und B-Ketten, die die geeignete Aminosäuresubstitution enthalten, gemäß bekannten Verfahren chemisch synthetisiert werden und die modifizierten A- und B-Ketten miteinander durch Aufbau von Disulfidbrücken zwischen A(7)Cys und B(7)Cys und zwischen A(20)Cys und B(19)-Cys und der internen A-Kettenbrücke zwischen A(6)Cys und A(11)Cys verknüpft werden.

35 14. Injizierbare Lösungen mit Insulin-Aktivität, dadurch gekennzeichnet, daß sie ein Analog von Humaninsulin nach Anspruch 1 oder ein pharmazeutisch annehmbares Salz desselben in wäßriger Lösung, vorzugsweise bei neutralem pH, enthalten.

40

45

50


55

Patentansprüche für folgenden Vertragsstaat : AT

1. Ein Verfahren zur Herstellung von Analoga von Humaninsulin der Formel I

5

A-Kette



20

25

B-Kette


25

worin wenigstens ein, aber nicht mehr als sieben der Xe dieselben oder verschiedene Aminosäurerest-substitutionen sind, deren Nettofunktion es ist, dem Molekül dieselbe Ladung oder eine größere negative Ladung bei neutralem pH als diejenige von Humaninsulin zu verleihen, wobei die restlichen Xe die natürlichen Aminosäurereste von Humaninsulin an der entsprechenden Position im Insulin-Molekül sind, mit der Maßgabe, daß es wenigstens eine Substitution in der B-Kette gibt und daß, wenn X in Position B(5) Ala ist, X in Position B(9) Leu ist, X in Position B(10) Asn oder Leu ist, X in Position B(12) Asn ist oder X in Position B(26) Ala ist, dann wenigstens eines der restlichen Xe verschieden ist von den Aminosäureresten von Humaninsulin an der entsprechenden Position im Insulin-Molekül, und mit der weiteren Maßgabe, daß X in Position B(5) nicht Asp sein kann und X in Position B(12) nicht Glu sein kann, und wobei ein oder mehrere Aminosäurereste von den N- und/oder C-terminalen Enden der A- und/oder B-Kette entfernt werden sein können, mit der zusätzlichen Maßgabe, daß, wenn X in einer oder mehreren der Positionen B(1), B(2), B(5), B(9), B(10), B(27) oder B(28) Ala ist, dann wenigstens eines von allen Xen, mit Ausnahme von jedem X, das in Position B(1), B(2), B(5), B(9), B(10), B(27) und/oder B(28) Ala ist, verschieden ist von den Aminosäureresten von Humaninsulin an der entsprechenden Position im Insulin-Molekül, wobei ein Hefestamm, der ein replizierbares Expressionsvehikel enthält, das eine DNA-Sequenz umfaßt, die einen Vorläufer des Analogs von Insulin kodiert, in einem geeigneten Nährstoffmedium kultiviert wird und der Vorläufer aus dem Kulturmedium gewonnen und in das neuartige Analog von Insulin durch enzymatische und chemische in-vitro-Umwandlung umgewandelt wird.

50

55

2. Ein Verfahren zur Herstellung von Analoga von Humaninsulin der Formel I



worin wenigstens ein, aber nicht mehr als sieben der Xe dieselben oder verschiedene Aminosäurerestsubstitutionen sind, deren Nettofunktion es ist, dem Molekül dieselbe Ladung oder eine größere negative Ladung bei neutralem pH als diejenige von Humaninsulin zu verleihen, wobei die restlichen Xe die natürlichen Aminosäurereste von Humaninsulin an der entsprechenden Position im Insulin-Molekül sind, mit der Maßgabe, daß es wenigstens eine Substitution in der B-Kette gibt und daß, wenn X in Position B(5) Ala ist, X in Position B(9) Leu ist, X in Position B(10) Asn oder Leu ist, X in Position B(12) Asn ist oder X in Position B(26) Ala ist, dann wenigstens eines der restlichen Xe verschieden ist von den Aminosäureresten von Humaninsulin an der entsprechenden Position im Insulin-Molekül, und mit der weiteren Maßgabe, daß X in Position B(5) nicht Asp sein kann und X in Position B(12) nicht Glu sein kann, und wobei ein oder mehrere Aminosäurereste von den N- und/oder C-terminalen Enden der A- und/oder B-Kette entfernt werden können, mit der zusätzlichen Maßgabe, daß, wenn X in einer oder mehreren der Positionen B(1), B(2), B(5), B(9), B(10), B(27) oder B(28) Ala ist, dann wenigstens eines von allen Xen, mit Ausnahme von jedem X, das in Position B(1), B(2), B(5), B(9), B(10), B(27) und/oder B(28) Ala ist, verschieden ist von den Aminosäureresten von Humaninsulin an der entsprechenden Position im Insulin-Molekül,

wobei ein biosynthetischer Vorläufer der allgemeinen Formel II


40

45

50

55

A-Kette




B-Kette

25 worin Q_n eine Peptidkette mit n natürlich auftretenden Aminosäureresten ist, R Lys oder Arg ist, n eine ganze Zahl von 0 bis 33 ist, m 0 oder 1 ist und die Xe wie oben definiert sind, mit der Maßgabe, daß die Peptidkette $-Q_n-R$ nicht zwei benachbarte basische Aminosäuren enthält, mit einem L-Threoninester in der Gegenwart von Trypsin oder einem Trypsin-Derivat zur Reaktion gebracht wird, gefolgt von der Umwandlung des erhaltenen Threoninesters des Analogs von Humaninsulin in das Analog von Humaninsulin.

3. Ein Verfahren zur Herstellung von Analoga von Humaninsulin der Formel I

A-Kette




B-Kette

50 worin wenigstens ein, aber nicht mehr als sieben der Xe dieselben oder verschiedene Aminosäurerest-
51 substitutionen sind, deren Nettofunktion es ist, dem Molekül dieselbe Ladung oder eine größere
52 negative Ladung bei neutralem pH als diejenige von Humaninsulin zu verleihen, wobei die restlichen Xe
53 die natürlichen Aminosäurereste von Humaninsulin an der entsprechenden Position im Insulin-Molekül
54 sind, mit der Maßgabe, daß es wenigstens eine Substitution in der B-Kette gibt und daß, wenn X in
55 Position B(5) Ala ist, X in Position B(9) Leu ist, X in Position B(10) Asn oder Leu ist, X in Position B(12)
Asn ist oder X in Position B(26) Ala ist, dann wenigstens eines der restlichen Xe verschieden ist von
den Aminosäureresten von Humaninsulin an der entsprechenden Position im Insulin-Molekül, und mit

der weiteren Maßgabe, daß X in Position B(5) nicht Asp sein kann und X in Position B(12) nicht Glu sein kann, und wobei ein oder mehrere Aminosäurereste von den N- und/oder C-terminalen Enden der A- und/oder B-Kette entfernt worden sein können, mit der zusätzlichen Maßgabe, daß, wenn X in einer oder mehreren der Positionen B(1), B(2), B(5), B(9), B(10), B(27) oder B(28) Ala ist, dann wenigstens eines von allen Xen, mit Ausnahme von jedem X, das in Position B(1), B(2), B(5), B(9), B(10), B(27) und/oder B(28) Ala ist, verschieden ist von den Aminosäureresten von Humaninsulin an der entsprechenden Position im Insulin-Molekül,
wobei ein biosynthetischer Vorläufer der allgemeinen Formel III

70

A-Kette

25

30


B-Kette

worin V und T jeweils Lys oder Arg sind und die Xe wie oben definiert sind, mit Trypsin und Carboxypeptidase B in wäßriger Lösung zur Reaktion gebracht wird und das Analog von Humaninsulin aus der Reaktionsmischung gewonnen wird.

35

4. Ein Verfahren zur Herstellung von Analoga von Humaninsulin der Formel I

40

A-Kette

55

B-Kette

5 worin wenigstens ein, aber nicht mehr als sieben der Xe dieselben oder verschiedene Aminosäurerestsubstitutionen sind, deren Nettofunktion es ist, dem Molekül dieselbe Ladung oder eine größere negative Ladung bei neutralem pH als diejenige von Humaninsulin zu verleihen, wobei die restlichen Xe die natürlichen Aminosäurereste von Humaninsulin an der entsprechenden Position im Insulin-Molekül sind, mit der Maßgabe, daß es wenigstens eine Substitution in der B-Kette gibt und daß, wenn X in Position B(5) Ala ist, X in Position B(9) Leu ist, X in Position B(10) Asn oder Leu ist, X in Position B(12) Asn ist oder X in Position B(26) Ala ist, dann wenigstens eines der restlichen Xe verschieden ist von den Aminosäureresten von Humaninsulin an der entsprechenden Position im Insulin-Molekül, und mit der weiteren Maßgabe, daß X in Position B(5) nicht Asp sein kann und X in Position B(12) nicht Glu sein kann, und wobei ein oder mehrere Aminosäurereste von den N- und/oder C-terminalen Enden der A- und/oder B-Kette entfernt werden können, mit der zusätzlichen Maßgabe, daß, wenn X in einer oder mehreren der Positionen B(1), B(2), B(5), B(9), B(10), B(27) oder B(28) Ala ist, dann wenigstens eines von allen Xen, mit Ausnahme von jedem X, das in Position B(1), B(2), B(5), B(9), B(10), B(27) und/oder B(28) Ala ist, verschieden ist von den Aminosäureresten von Humaninsulin an der entsprechenden Position im Insulin-Molekül,

10 wobei die Analoga von Insulin, die die geeigneten Aminosäuresubstitutionen enthalten, gemäß bekannten Verfahren chemisch synthetisiert werden oder A- und B-Ketten, die die geeignete Aminosäuresubstitution enthalten, gemäß bekannten Verfahren chemisch synthetisiert werden und die modifizierten A- und B-Ketten miteinander durch Aufbau von Disulfidbrücken zwischen A(7)Cys und B(7)Cys und zwischen A(20)Cys und B(19)Cys und der internen A-Kettenbrücke zwischen A(6)Cys und A(11)Cys verknüpft werden.

15 5. Ein Verfahren nach einem der Ansprüche 1 bis 4, wobei die Aminosäurerestsubstitutionen im hergestellten Analog von Insulin hydrophiler sind als der Aminosäurerest von Humaninsulin an der entsprechenden Position im Insulin-Molekül.

20 6. Ein Verfahren nach einem der Ansprüche 1 bis 5, wobei die Aminosäuresubstitutionen im hergestellten Analog von Insulin ausgewählt sind aus der Gruppe, die aus Asp, Glu, Ser, Thr, His und Ile besteht.

25 7. Ein Verfahren nach Anspruch 6, wobei die Aminosäurerestsubstitutionen Asp und/oder Glu sind.

30 8. Ein Verfahren nach einem der Ansprüche 1 bis 7, wobei wenigstens ein X in Position B(9), B(10), B(12), B(26) oder B(27) des hergestellten Analogs von Insulin verschieden ist von dem Aminosäurerest an der entsprechenden Stelle im Molekül von Humaninsulin.

35 9. Ein Verfahren nach Anspruch 8, wobei wenigstens ein X in Position B(9), B(12), B(27) oder B(28) verschieden ist von dem Aminosäurerest an der entsprechenden Stelle im Molekül von Humaninsulin.

40 10. Ein Verfahren nach einem der Ansprüche 1 bis 4, wobei, im hergestellten Analog von Insulin, X in Position B27 Glu ist, X in Position B12 Ile oder Tyr ist, X in Position A21 Asp ist und in Position B27 Glu ist, X in Position B9 Asp ist, X in Position A21 und in Position B9 Asp ist und in Position B27 Glu ist, X in Position A8 His ist, in Position B9 Asp ist und in Position B27 Glu ist, X in Position B10 Asp ist, X in Position B9 Asp ist und in Position B27 Glu ist oder X in Position B28 Asp ist.

45 11. Ein Verfahren nach einem der Ansprüche 1 bis 4, wobei dem hergestellten Analog von Insulin bis zu vier Aminosäurereste am N-Terminus der B-Kette und/oder bis zu fünf Aminosäurereste am C-terminalen Ende der B-Kette fehlen.


50 12. Ein Verfahren nach Anspruch 2, wobei dem hergestellten Analog von Insulin der B(1)-Aminosäurerest und/oder der B(30)-Aminosäurerest fehlt.

Revendications

Revendications pour les Etats contractants suivants : BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

1. Analogues d'insuline humaine à action rapide, caractérisés en ce qu'ils ont la formule I

5



20

dans laquelle au moins un mais pas plus de sept des X sont des substitutions de résidus d'aminoacides identiques ou différentes dont la fonction nette est de communiquer à la molécule la même charge ou une charge négative plus importante à pH neutre que celle de l'insuline humaine, les autres X étant les résidus d'aminoacides naturels de l'insuline humaine aux positions correspondantes dans la molécule d'insuline, à condition qu'il y ait au moins une substitution dans la chaîne B et que, lorsque X en position B(5) est Ala, X en position B(9) est Leu, X en position B(10) est Asn ou Leu, X en position B(12) est Asn ou X en position B(26) est Ala, au moins l'un des autres X soit différent du résidu d'aminoacide de l'insuline humaine à la position correspondante dans la molécule d'insuline, et à la condition supplémentaire que X en position B(5) ne puisse pas être Asp et que X en position B(12) ne puisse pas être Glu; et dans laquelle un ou plusieurs résidus d'aminoacides peuvent avoir été supprimés des extrémités N- et/ou C-terminales de la chaîne A et/ou de la chaîne B, avec la condition supplémentaire selon laquelle, lorsque X est Ala en une ou plusieurs des positions B(1), B(2), B(5), B(9), B(10), B(27) ou B(28), au moins l'un quelconque des X, sauf les X qui sont Ala en position B(1), B(2), B(5), B(9), B(10), B(27) et/ou B(28), est différent du résidu d'aminoacide de l'insuline humaine à la position correspondante dans la molécule d'insuline.

2. Analogues d'insuline selon la revendication 1, dans lesquels les substitutions de résidus d'aminoacides sont plus hydrophiles que les résidus d'aminoacides de l'insuline humaine situés aux positions correspondantes dans la molécule d'insuline.

3. Analogues d'insuline humaine selon la revendication 1, dans lesquels les substitutions de résidus d'aminoacides sont choisies dans le groupe constitué par Asp, Glu, Ser, Thr, His et Ile.

4. Analogues d'insuline humaine selon la revendication 1, dans lesquels les substitutions de résidus d'aminoacides sont Asp et/ou Glu.

5. Analogues d'insuline humaine selon la revendication 1, dans lesquels au moins un X en position B(9), B(10), B(12), B(26), B(27) ou B(28) est différent du résidu d'aminoacide au site correspondant dans la molécule de l'insuline humaine.

6. Analogues d'insuline humaine selon la revendication 1, dans lesquels au moins un X en position B(9), B(12), B(27) ou B(28) est différent du résidu d'aminoacide au site correspondant dans la molécule de l'insuline humaine.

7. Analogues d'insuline humaine selon la revendication 1, dans lesquels X est Glu en position B27, X est Ile ou Tyr en position B12, X est Asp en position A21 et Glu en position B27, X est Asp en position B9, X est Asp en position A21 et en position B9 et Glu en position B27, X est His en position A8, Asp en

position B9 et Glu en position B27, X est Asp en position B10, X est Asp en position B9 et Glu en position B27, ou X est Asp en position B28.

8. Analogues d'insuline humaine selon la revendication 1, caractérisés en ce que sont absents jusqu'à quatre résidus d'aminoacides à l'extrémité N-terminale de la chaîne B et/ou jusqu'à cinq résidus d'aminoacides à l'extrémité C-terminale de la chaîne B.


9. Analogues d'insuline humaine selon la revendication 8, caractérisés en ce que sont absents le résidu d'aminoacide B(1) et/ou le résidu d'aminoacide B(30).

10. Méthode de préparation d'analogues d'insuline humaine selon la revendication 1, dans laquelle on cultive, dans un milieu nutritif convenable, une souche de levure contenant un véhicule d'expression répliable comprenant une séquence d'ADN codant pour un précurseur de l'analogue d'insuline, on récupère le précurseur à partir du milieu de culture et on le transforme en le nouvel analogue d'insuline par conversion enzymatique et chimique in vitro.

11. Méthode de préparation d'analogues d'insuline humaine selon la revendication 1, dans laquelle on fait réagir un précurseur biosynthétique de formule générale II

20

chaîne A



II


40 dans laquelle Q_n est une chaîne peptidique de n résidus d'aminoacides naturels, R est Lys ou Arg, n est un entier de 0 à 33, m est 0 ou 1, et les X ont la définition indiquée ci-dessus, sous réserve que la chaîne peptidique $-Q_n-R-$ ne contienne pas deux résidus d'aminoacides basiques adjacents, avec un ester de L-thréonine en présence de trypsine ou d'un dérivé de trypsine, puis on transforme par des méthodes connues l'ester de thréonine de l'analogue d'insuline humaine obtenu en l'analogue d'insuline humaine.

45

12. Méthode de préparation d'analogues d'insuline humaine selon la revendication 1, dans laquelle on fait réagir un précurseur biosynthétique de formule générale III

50

55




20 dans laquelle V et T sont chacun Lys ou Arg et les X ont la définition indiquée ci-dessus, avec de la trypsiné et de la carboxypeptidase B en solution aqueuse, et on récupère l'analogue d'insuline humaine à partir du mélange réactionnel.

25 13. Procédé de préparation d'analogues d'insuline humaine selon la revendication 1, dans lequel on effectue selon des méthodes connues la synthèse chimique des analogues d'insuline contenant les substitutions d'aminoacides appropriées, ou on effectue selon des méthodes connues la synthèse chimique des chaînes A et B modifiées contenant les substitutions d'aminoacides appropriées et on relie l'une à l'autre les chaînes A et B en établissant des ponts disulfure entre A(7)Cys et B(7)Cys et entre A(20)Cys et B(19)Cys et le pont interne de la chaîne A entre A(6)Cys et A(11)Cys.

30 14. Solutions injectables à activité d'insuline, caractérisées en ce qu'elles contiennent un analogue d'insuline humaine selon la revendication 1 ou un de ses sels pharmaceutiquement acceptables en solution aqueuse, de préférence à pH neutre.

35 Revendications pour l'Etat contractant suivant : AT

1. Méthode de préparation d'analogues d'insuline humaine de formule I




55 55 dans laquelle au moins un mais pas plus de sept des X sont des substitutions de résidus d'aminoacides identiques ou différentes dont la fonction nette est de communiquer à la molécule la même charge ou une charge négative plus importante à pH neutre que celle de l'insuline humaine, les autres X étant les résidus d'aminoacides naturels de l'insuline humaine aux positions correspondantes dans la

molécule d'insuline, à condition qu'il y ait au moins une substitution dans la chaîne B et que, lorsque X en position B(5) est Ala, X en position B(9) est Leu, X en position B(10) est Asn ou Leu, X en position B(12) est Asn ou X en position B(26) est Ala, au moins l'un des autres X soit différent du résidu d'aminoacide de l'insuline humaine à la position correspondante dans la molécule d'insuline, et à la condition supplémentaire que X en position B(5) ne puisse pas être Asp et que X en position B(12) ne puisse pas être Glu; et dans laquelle un ou plusieurs résidus d'aminoacides peuvent avoir été supprimés des extrémités N- et/ou C-terminales de la chaîne A et/ou de la chaîne B, avec la condition supplémentaire selon laquelle, lorsque X est Ala en une ou plusieurs des positions B(1), B(2), B(5), B(9), B(10), B(27) ou B(28), au moins l'un quelconque des X, sauf les X qui sont Ala en position B(1), B(2), B(5), B(9), B(10), B(27) et/ou B(28), est différent du résidu d'aminoacide de l'insuline humaine à la position correspondante dans la molécule d'insuline,


dans laquelle on cultive, dans un milieu nutritif convenable, une souche de levure contenant un véhicule d'expression répllicable comprenant une séquence d'ADN codant pour un précurseur de l'analogue d'insuline, on récupère le précurseur à partir du milieu de culture et on le transforme en le nouvel analogue d'insuline par conversion enzymatique et chimique *in vitro*.

2. Méthode de préparation d'analogues d'insuline humaine de formule I



dans laquelle au moins un mais pas plus de sept des X sont des substitutions de résidus d'aminoacides identiques ou différents dont la fonction nette est de communiquer à la molécule la même charge ou une charge négative plus importante à pH neutre que celle de l'insuline humaine, les autres X étant les résidus d'aminoacides naturels de l'insuline humaine aux positions correspondantes dans la molécule d'insuline, à condition qu'il y ait au moins une substitution dans la chaîne B et que, lorsque X en position B(5) est Ala, X en position B(9) est Leu, X en position B(10) est Asn ou Leu, X en position B(12) est Asn ou X en position B(26) est Ala, au moins l'un des autres X soit différent du résidu d'aminoacide de l'insuline humaine à la position correspondante dans la molécule d'insuline, et à la condition supplémentaire que X en position B(5) ne puisse pas être Asp et que X en position B(12) ne puisse pas être Glu; et dans laquelle un ou plusieurs résidus d'aminoacides peuvent avoir été supprimés des extrémités N- et/ou C-terminales de la chaîne A et/ou de la chaîne B, avec la condition supplémentaire selon laquelle, lorsque X est Ala en une ou plusieurs des positions B(1), B(2), B(5), B(9), B(10), B(27) ou B(28), au moins l'un quelconque des X, sauf les X qui sont Ala en position B(1), B(2), B(5), B(9), B(10), B(27) et/ou B(28), est différent du résidu d'aminoacide de l'insuline humaine à la position correspondante dans la molécule d'insuline, dans laquelle on fait réagir un précurseur biosynthétique de formule II

chaîne A




chaîne B

II

20 dans laquelle Q_n est une chaîne peptidique de n résidus d'aminoacides naturels, R est Lys ou Arg, n est un entier de 0 à 33, m est 0 ou 1, et les X ont la définition indiquée ci-dessus, sous réserve que la chaîne peptidique -Q_n-R- ne contienne pas deux résidus d'aminoacides basiques adjacents, avec un ester de L-thréonine en présence de trypsine ou d'un dérivé de trypsine, puis on transforme l'ester de thréonine de l'analogue d'insuline humaine obtenu en l'analogue d'insuline humaine.

25 3. Méthode de préparation d'analogues d'insuline humaine de formule I




chaîne B

I


45 dans laquelle au moins un mais pas plus de sept des X sont des substitutions de résidus d'aminoacides identiques ou différentes dont la fonction nette est de communiquer à la molécule la même charge ou une charge négative plus importante à pH neutre que celle de l'insuline humaine, les autres X étant les résidus d'aminoacides naturels de l'insuline humaine aux positions correspondantes dans la molécule d'insuline, à condition qu'il y ait au moins une substitution dans la chaîne B et que, lorsque X en position B(5) est Ala, X en position B(9) est Leu, X en position B(10) est Asn ou Leu, X en position B(12) est Asn ou X en position B(26) est Ala, au moins l'un des autres X soit différent du résidu d'aminoacide de l'insuline humaine à la position correspondante dans la molécule d'insuline, et à la condition supplémentaire que X en position B(5) ne puisse pas être Asp et que X en position B(12) ne puisse pas être Glu; et dans laquelle un ou plusieurs résidus d'aminoacides peuvent avoir été supprimés des extrémités N- et/ou C-terminales de la chaîne A et/ou de la chaîne B, avec la condition supplémentaire selon laquelle, lorsque X est Ala en une ou plusieurs des positions B(1), B(2), B(5), B(9), B(10), B(27) ou B(28), au moins l'un quelconque des X, sauf les X qui sont Ala en position B(1), B(2), B(5), B(9), B(10), B(27) et/ou B(28), est différent du résidu d'aminoacide de l'insuline humaine à la position correspondante dans la molécule d'insuline,

55 dans laquelle on fait réagir un précurseur biosynthétique de formule générale III



20 dans laquelle V et T sont chacun Lys ou Arg et les X ont la définition indiquée ci-dessus, avec de la trypsine et de la carboxypeptidase B en solution aqueuse, et on récupère l'analogue d'insuline humaine à partir du mélange réactionnel.

4. Procédé de préparation d'analogues d'insuline humaine de formule I



40 dans laquelle au moins un mais pas plus de sept des X sont des substitutions de résidus d'aminoacides identiques ou différentes dont la fonction nette est de communiquer à la molécule la même charge ou une charge négative plus importante à pH neutre que celle de l'insuline humaine, les autres X étant les résidus d'aminoacides naturels de l'insuline humaine aux positions correspondantes dans la molécule d'insuline, à condition qu'il y ait au moins une substitution dans la chaîne B et que, lorsque X en position B(5) est Ala, X en position B(9) est Leu, X en position B(10) est Asn ou Leu, X en position B(12) est Asn ou X en position B(26) est Ala, au moins l'un des autres X soit différent du résidu d'aminoacide de l'insuline humaine à la position correspondante dans la molécule d'insuline, et à la condition supplémentaire que X en position B(5) ne puisse pas être Asp et que X en position B(12) ne puisse pas être Glu; et dans laquelle un ou plusieurs résidus d'aminoacides peuvent avoir été supprimés des extrémités N- et/ou C-terminales de la chaîne A et/ou de la chaîne B, avec la condition supplémentaire selon laquelle, lorsque X est Ala en une ou plusieurs des positions B(1), B(2), B(5), B(9), B(10), B(27) ou B(28), au moins l'un quelconque des X, sauf les X qui sont Ala en position B(1), B(2), B(5), B(9), B(10), B(27) et/ou B(28), est différent du résidu d'aminoacide de l'insuline humaine à la position correspondante dans la molécule d'insuline.

45 dans lequel on effectue selon des méthodes connues la synthèse chimique des analogues d'insuline contenant les substitutions d'aminoacides appropriées, ou on effectue selon des méthodes connues la synthèse chimique des chaînes A et B contenant les substitutions d'aminoacides appro-

priées et on relie l'une à l'autre les chaînes A et B modifiées en établissant des ponts disulfure entre A-(7)Cys et B(7)Cys et entre A(20)Cys et B(19)Cys et le pont interne de la chaîne A entre A(6)Cys et A-(11)Cys.

5. Méthode selon l'une quelconque des revendications 1 à 4, dans laquelle les substitutions de résidus d'aminoacides dans l'analogue d'insuline préparé sont plus hydrophiles que les résidus d'aminoacides de l'insuline humaine situés aux positions correspondantes dans la molécule d'insuline.
10. Méthode selon l'une quelconque des revendications 1 à 5, dans laquelle les substitutions de résidus d'aminoacides dans l'analogue d'insuline préparé sont choisies dans le groupe constitué par Asp, Glu, Ser, Thr, His et Ile.
15. Méthode selon la revendication 6, dans laquelle les substitutions de résidus d'aminoacides sont Asp et/ou Glu.
8. Méthode selon l'une quelconque des revendications 1 à 7, dans laquelle au moins un X en position B-(9), B(10), B(12), B(26), B(27) ou B(28) de l'analogue d'insuline préparé est différent du résidu d'aminoacide au site correspondant dans la molécule de l'insuline humaine.
20. 9. Méthode selon la revendication 8, dans laquelle au moins un X en position B(9), B(12), B(27) ou B(28) est différent du résidu d'aminoacide au site correspondant dans la molécule de l'insuline humaine.
25. 10. Méthode selon l'une quelconque des revendications 1 à 4, dans laquelle, dans l'analogue d'insuline préparé, X est Glu en position B27, X est Ile ou Tyr en position B12, X est Asp en position A21 et Glu en position B27, X est Asp en position B9, X est Asp en position A21 et en position B9 et Glu en position B27, X est His en position A8, Asp en position B9 et Glu en position B27, X est Asp en position B10, X est Asp en position B9 et Glu en position B27, ou X est Asp en position B28.
30. 11. Méthode selon l'une quelconque des revendications 1 à 4, dans laquelle, dans l'analogue d'insuline préparé, sont absents jusqu'à quatre résidus d'aminoacides à l'extrémité N-terminale de la chaîne B et/ou jusqu'à cinq résidus d'aminoacides à l'extrémité C-terminale de la chaîne B.
12. Méthode selon la revendication 2, dans laquelle, dans l'analogue d'insuline préparé, sont absents le résidu d'aminoacide B(1) et/ou le résidu d'aminoacide B(30).

35

40

45

50

55

Fig. 1

A 35-mer	B 43-mer	C 32-mer	D 37-mer	E 36-mer
—	—	—	—	—
36-mer	42-mer	34-mer	37-mer	33-mer

Lys Arg Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr Leu Val Cys

Hinf I Hpa I Nla IV HindIII Rsa I
 AA AGA TTC GTT AAC CAA CAC TTG TGC GGT TCC CAC TTG GTT GAA GCT TTC TAC TTG GTT TGC-
 AAG CAA TTG GTT GTG AAC AGC CCA AGG GTG AAC CAA CTT CGA AAC ATG AAC ATG ACG ACG

Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala Ala Lys Gly Ile Val Glu Gln Cys Cys Thr

Hph I MboII MstII, DdeI Dde I Taq I Rsa I
GGT GAA AGA GGT TTC TTC TAC ACT CCT AAG GCT GCT AAG GGT ATT GTC GAA CAA TGC TGT ACC-
 CCA CTT TCT CCA AAG AAG ATG TGA GGA TTC CGA CGA TTC CCA TAA CAG CTT GTT ACG ACA TGG

Ser Ile Cys Ser Leu Tyr Gln Leu Glu Asn Tyr Cys Asn

TCC ATC TGC TCC TTG TAC CAA TTG GAA AAC TAC TGC AAC TAG ACG CAG CCC GCA GGC T Xba I
 AGG TAG ACG AGG AAC ATG GTT AAC CTT TTG ATG ACG TGT ATC TGC GTC GGG CGT CCG AGA TC

Rsa I (-PvuII) Hga I Hga I Xba I

Fig.2




Fig. 3




Fig. 4




Fig. 5

